Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
NATIONAL AIDS CONTROL ORGANISATION | ICMR – NATIONAL INSTITUTE OF MEDICAL STATISTICSMINISTRY OF HEALTH & FAMILY WELFARE, GOVERNMENT OF INDIA
INDIA HIV ESTIMATES 2019
ii
Suggested citation:
National AIDS Control Organization & ICMR-National Institute of Medical Statistics (2020). India HIV Estimates 2019: Report. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India.
For additional information about ‘India HIV Estimates 2019: Report’, please contact:
Surveillance & Epidemiology-Strategic Information DivisionNational AIDS Control Organisation (NACO)Ministry of Health and Family Welfare, Government of India 6th and 9th Floor Chanderlok, 36, Janpath, New Delhi, 110001
INDIA HIV ESTIMATES 2019
iii
INDIA HIVESTIMATES 2019 REPORT
NATIONAL AIDS CONTROL ORGANISATION | ICMR – NATIONAL INSTITUTE OF MEDICAL STATISTICSMINISTRY OF HEALTH & FAMILY WELFARE
GOVERNMENT OF INDIA
GoI/NACO/Surveillance/HIV Estimates 2019/200720
INDIA HIV ESTIMATES 2019
iv
INDIA HIV ESTIMATES 2019
v
Disease burden estimations are fundamental to public health policy formulation, resource allocation and implementation design. They further inform impacts of the public health interventions. In view of the importance of disease burden estimates, World Health Organization (WHO) has been publishing global burden disease estimates since 2000. For HIV, The Joint United Nations Programme on HIV/AIDS (UNAIDS) has established a robust system of periodic estimation which is adopted by most member countries.
HIV disease burden estimation is integral to Surveillance and Epidemiology under National AIDS Control Programme (NACP) since 1998. The first round used indigenous spread-sheet based method using findings from the first round of HIV sentinel surveillance. In 2006, HIV burden estimation under NACP took a methodological leap with availability of community-based HIV prevalence estimates from National Family Health Survey (NFHS) in select States and then also adopting WHO/UNAIDS recommended Workbook and Spectrum method. Since then, the process and tools have continued to evolve as the new evidences on assumptions emerge and models are subsequently improved by UNAIDS.
The HIV Estimates 2019 is the latest round providing updated estimates on the key indicators of prevalence, incidence, mortality, and elimination of mother to child transmission (EMTCT) need by States and UTs. The methods improve from previous round in terms of use of most recent fertility estimates, routine testing data of pregnant women and use of NFHS-IV to inform epidemiological curves and other assumptions. The results highlight that while the overall impact on the HIV/AIDS epidemic continue to be significant, there are pockets which require a very intensive and integrated actions by all Stakeholders to bend the epidemic curve. These estimates are further being disaggregated by districts and analyzed in-depth to provide both macro and micro level of evidences for policy making, local level planning and progress monitoring.
The HIV Estimates 2019 report has come out at an opportune moment. It provides evidence on how much progress has been made on at least three of the 2020 fast-track targets and thus provide a baseline for the programme as NACP designs its contour for the next five years. It also indicates locations which need a much more concerted eff ort. I am confident that all Stakeholders will use this report to further enhance evidence driven implementations towards achieving end of AIDS as a public health threat by 2030.
(Arti Ahuja)
FOREWORD
INDIA HIV ESTIMATES 2019
vi
INDIA HIV ESTIMATES 2019
vii
lndia is currently responding to the COVlD-19 pandemic. The SARS-CoV-2 virus has impacted almost all aspects of life and the national HIV/AIDS programme is not an exception. High-risk groups and migrants have been impacted severely being one of the most disadvantaged and marginalized. Movements of people, drugs, testing kits and all other commodities were adversely impacted limiting the availability and access to the services. Also, globally, evidence has emerged that HIV-infected people are more at risk of COVID-19 death compared to HIV-negative patients. The challenges for the National AIDS Control Programme have multiplied with COVID-19 pandemic.
Given the current context, HIV Estimations 2019 report is a timely publication providing the latest evidence on the magnitude and directions of the HIV/AIDS epidemic. The report details the methodology, presents the findings on epidemiological indicators of prevalence-incidence-mortality-EMTCT need and finally discusses the implications for the National AIDS Control Programme. The report further provides evidence on progress towards 2020 fast-track targets. While progress on treatment aspect has been significant, there is still a lot to be done on the prevention of new HIV infections and the elimination of mother to child transmission of HIV. The continued diversity in the epidemic has been reflected systematically with higher prevalence and incidence in the north-eastern region but the high volume of overall size and new infections in the southern, western, central and eastern regions. Knowledge about this diversity will be vital to re-strategize the approaches under the national AIDS response.
HIV Estimations 2019 report concludes the 16th round of surveillance and estimation activities undertaken by NACP. The round directly engaged thousands of front-line workers, programme managers, epidemiologists, demographers, biostatisticians and microbiologists under the leadership of Dr. Shobini Rajan (Deputy Director General, Surveillance and Epidemiology, MoHFW, Gol). I congratulate all of them for successful implementation of another round of one of the world's largest and most diverse surveillance system. I am confident that the rich and timely evidence presented in this report will be used by all stakeholders to fast-track the national AlDS response.
(Alok Saxena )
PREFACE
INDIA HIV ESTIMATES 2019
viii
INDIA HIV ESTIMATES 2019
ix
PREFACE
Dr. M. Vishnu Vardhana RaoM.Sc(Stat), M.Tech(IT), PhD(Stat)Director
ICMR - NATIONAL INSTITUTE OF MEDICAL STATISTICS(INDIAN COUNCIL OF MEDICAL RESEARCH)
Department of Health Research, Ministry of Healthand Family Welfare, Government of India
Ansari Nagar, New Delhi - 110029
Phone : 91-11-26588803Telefax : 91-11-26589635Email : [email protected] : [email protected]
(M. Vishnu Vardhana Rao)Director, ICMR-NIMS
Chair National Working Group on HIV Estimations
India has successfully generated HIV estimates under the 2019 estimations round for national and State/Union Territory for the following key parameters: adult HIV prevalence, number of people living with HIV, HIV incidence per 1,000 uninfected population, number of annual new HIV infections, AIDS-related mortality per 100,000 population, number of annual AIDS-related deaths, and finally the need for services to eliminate mother-to-child transmission of HIV in India.
These estimates are developed by the National Working Group on HIV Estimations (NWG) led by the Indian Council of Medical Research – National Institute of Medical Statistics (ICMR-NIMS) – which is the apex technical body for HIV estimations in the country – and the National AIDS Control Organisation (NACO). NWG members include specialists in Demography/Statistics/Epidemiology, Regional Institutes and Medical Colleges, and M&E off icers/ epidemiologists from State AIDS Control Societies, independent national experts, and experts from UNAIDS India, WHO India and PEPFAR/CDC India. Technical advice has also been sought from specialists from the UNAIDS regional and headquarters and Avenir Health. The Technical Resource Group on HIV Surveillance and Estimations (TRG) is the oversight body, who have reviewed and validated the method and results of 2019 HIV estimates round.
2019 round of HIV estimates have been generated using the UNAIDS recommended Spectrum software revision 5.8. Latest demographic, epidemiological and programme data available in the country were updated, with curve-fitting using ‘EPP Classic model’ done with assumptions and parameters informed by available national data as much as possible. These 2019 estimates cannot be compared directly with estimates published previously as the current estimates are based on new assumptions. It is stemmed from evidence and enhancements made in the Spectrum modelling tool, and the updated latest demographic, surveillance and programme data, thus leading to a refined and improved quality.
As the Chairperson of the NWG on HIV estimates, I would like to congratulate all those who have been part of this modelling exercise and worked tirelessly to bring out this critical information for the National AIDS Control Programme in India. Special thanks to Dr. Damodar Sahu, PI & Focal person of Estimation, ICMR-NIMS and his team. I encourage all stakeholders to use this Technical Report on 2019 HIV Estimates as a guide for their decision making, planning and programmatic purposes.
INDIA HIV ESTIMATES 2019
x
INDIA HIV ESTIMATES 2019
xi
I must commend the National AIDS Control Organisation (NACO) and the Indian Council of Medical Research-National Institute of Medical Statistics (ICMR-NIMS) for publishing HIV estimates periodically for the past 20+ years: The most recent being under this 2019 estimations round. HIV estimates are a critical source of information on the HIV epidemic and a sound basis to be used as markers to assess the burden of the epidemic and inform programme planning, prioritization, monitoring and impact assessment.
The development of HIV estimations in India is a noteworthy collaborative, pragmatic and scientific one. It engages national experts from ICMR Regional Institutes, Medical Colleges, and State AIDS Control Societies – who are members of the National Working Group on HIV Estimations (NWG) development under the leadership of ICMR-NIMS and NACO, and under oversight of the senior national and international experts body: the Technical Resource Group on HIV Surveillance and Estimations (TRG) which includes UNAIDS, WHO and PEPFAR/CDC.
UNAIDS is very pleased to have provided technical and financial support to this critical work. The 2019 HIV estimates have been generated using the latest version of Spectrum software recommended by UNAIDS for the modelling work; with the latest nationally available demographic, epidemiological and programmatic data inputted to inform State/UT models, end ensuring scientific methodological rigour.
The 2019 HIV estimates provide latest information on the level and trend of adult HIV prevalence, number of people living with HIV, annual new HIV infections, annual AIDS-related deaths, and need for elimination of mother-to-child transmission of HIV services at the national level and across 35 States/UTs. This evidence is made available in a very timely manner as India enters a critical year in its AIDS response. 2020–21 may very likely mark the final year of the National AIDS Control Programme’s current phase IV. 2020 is also a critical year vis-à-vis national targets end-line year as mentioned in the National Strategic Plan 2017–24. This information will hence be very useful to inform stock-taking and HIV programme planning purposes towards the end of AIDS as a public health threat by 2030.
Finally, I would like to reiterate UNAIDS full and continued support to the HIV estimations work led by NACO and ICMR-NIMS and to the NWG and TRG. I remain convinced that with the evidence-based prioritization at local level, the community engagement, and the innovative implementation strategies, we will together advance India towards the end of AIDS.
Dr. Bilali CamaraMedical Epidemiologist
UNAIDS Country Director for India
MESSAGE
INDIA HIV ESTIMATES 2019
xii
INDIA HIV ESTIMATES 2019
xiii
Government of IndiaMinistry of Health & Family WelfareNational AIDS Control Organisation
9th Floor, Chandralok Building,36, Janpath, New Delhi, 110011
Biennial HIV Estimations is a key component of spectrum of Surveillance and Epidemiology activities under the National AIDS Control Programme. Being implemented since 1998, HIV Estimations 2019 is the latest in the series updating the epidemiological evidences nationally and by States/UTs. India’s topmost epidemiologist, demographers, bio-statisticians, community representatives with State and national programme managers have actively contributed in the successful completion of HIV Estimations 2019. We acknowledge the contributions made by all stakeholders engaged in the process.
The Technical Resource Group (TRG) for HIV Surveillance and Estimation, first under the chairpersonship of Shri Sanjeeva Kumar (former Special Secretary & DG, NACO, MoHFW, Gol) and now under the chairpersonship of Smt. Arti Ahuja (Additional Secretary & DG, NACO, MoHFW, Gol) and co-chairpersonship of Dr. Sanjay Mehendale (Former Addl. DG, ICMR) approved the process, methods and report for HIV Estimations 2019. Shri Alok Saxena (Joint Secretary, NACO) provided his guidance for timely completion of activities. Dr. D. C. S. Reddy, Prof. Arvind Pandey, Dr. Shashi Kant, Dr. Bilali Camara, Mx. Abhina Aher, Dr. John Stover, Mr Taoufik Bakkali, Dr. Melissa Nyendak, Dr. Laishram Ladu Singh, Dr. Rajesh Kumar, Dr. D. K. Shukla and Dr. Sanjay Dixit strengthened the exercise with their expertise and provided critical technical guidance at all stages as TRG members. Programmatic context for the exercise was provided by Dr. Sunil Gupta (Addl. DG, NACO), Dr. R. S. Gupta (Former DDG, NACO), Dr. Naresh Goel (DDG, NACO), Dr. Anoop Kumar Puri (DDG, NACO), Dr. Chinmoyee Das, Dr. Bhawani Singh Kushwaha, and Dr. Saiprasad Bhavsar (DD, NACO). We place on record our sincere thanks to NACO’s leadership and senior experts for providing vision, insights and support towards HIV Estimations 2019.
National Working Group (NWG), constituted by NACO, was instrumental in planning, organization, and execution of HIV Estimations 2019. Excellent leadership to the working group was provided by Dr. M. Vishnu Vardhana Rao (Director, ICMR-NIMS, New Delhi).
Dr. Pradeep Kumar (NACO) and Dr. Damodar Sahu (ICMR-NIMS), together with Ms. Nalini Chandra (UNAIDS lndia) and Dr. Arvind Kumar (NACO), anchored the implementation of HIV Estimations 2019. Dr. Sheela Godbole (ICMR-NARI, Pune), Dr. A. Elangovan (ICMR-NIE, Chennai), Dr. M. K. Saha (ICMR-NlCED, Kolkata), Dr. Sanjay Rai (AllMS, New Delhi), Dr. P. V. M. Lakshmi (PGIMER, Chandigarh) and Dr. T. Gambhir (RIMS, Imphal) enriched NWG with their insights into the epidemic for their respective regions. Dr. Srikala Acharya (Mumbai DACS), Dr. Pramod Devraj (Maharashtra SACS), Dr. Richard C. Lalramhluna (Mizoram SACS), Dr. Rajesh Gopal, Dr. Anup R. Amin (Gujarat SACS) and Dr. M. Janakiram (Tamil Nadu SACS) provided State perspective. Ms. Deepika Srivastava Joshi (CDC-DGHT India) and Dr. Rajatashuvra Adhikary (WHO lndia) provided international perspectives to the process. UNAIDS India supported the publication of HIV Estimations 2019 report. We acknowledge the contribution of each of them towards successful completion of HIV Estimations 2019.
Surveillance is information for action. HIV Estimations consolidates the most recent demographic, programmatic and surveillance evidences into key epidemiological parameters. We are confident that all stakeholders will use the latest evidences presented here to fine-tune their responses to further benefit the national AIDS response in the country.
(Shobini Rajan)
ACKNOWLEDGEMENT
110011
INDIA HIV ESTIMATES 2019
xiv
INDIA HIV ESTIMATES 2019
xv
ContentsAbbreviations ...................................................................................................................xviii
Executive Summary ...........................................................................................................xxi
01 Background ................................................................................................................ 1
02 Process ...................................................................................................................... 3
03 Method and Data Inputs ........................................................................................... 5
3.1 Overview ................................................................................................................................... 5
3.2 Spectrum Version 5.8 ............................................................................................................ 6
3.3 Key Methodological/Data Updates in the State/Union Territory Model ................................................................................................ 6
04 Results ...................................................................................................................... 9
4.1 Overview ................................................................................................................................. 10
4.2 Adult (15–49 years) HIV Prevalence ................................................................................. 10
4.3 Number of People Living with HIV ................................................................................... 12
4.4 HIV Incidence ..........................................................................................................................15
4.5 Annual New HIV Infections ................................................................................................. 17
4.6 AIDS-related Mortality ..........................................................................................................19
4.7 Annual AIDS-related Deaths ...............................................................................................19
4.8 Pregnant Women in Need of Prevention of Mother-to-Child Transmission Services ......................................................................... 22
05 Discussion ............................................................................................................... 23
INDIA HIV ESTIMATES 2019
xvi
Annexures .......................................................................................................................... 25
Annexure 1: Composition of the National Working Group on HIV Estimations 2019....................................................................................................................26
Annexure 2: Composition of Technical Resource Group on HIV Surveillance and Estimation ...............................................................................................33
Anenxure 3: State and Union Territory-wise summary of HIV Epidemic in 2019, India HIV Estimates 2019 ........................................................................35
Factsheets ...........................................................................................................................37
Andaman and Nicobar Islands ........................................................................................................38
Andhra Pradesh ...................................................................................................................................39
Arunachal Pradesh ............................................................................................................................. 40
Assam .......................................................................................................................................................41
Bihar .........................................................................................................................................................42
Chandigarh ............................................................................................................................................43
Chhattisgarh .........................................................................................................................................44
Daman and Diu .....................................................................................................................................45
Dadra and Nagar Haveli .....................................................................................................................46
Delhi ......................................................................................................................................................... 47
Goa...........................................................................................................................................................48
Gujarat ....................................................................................................................................................49
Haryana ..................................................................................................................................................50
Himachal Pradesh ................................................................................................................................51
Jammu and Kashmir and Ladakh ................................................................................................... 52
Jharkhand...............................................................................................................................................53
Karnataka ...............................................................................................................................................54
Kerala .......................................................................................................................................................55
INDIA HIV ESTIMATES 2019
xvii
Madhya Pradesh ..................................................................................................................................56
Maharashtra .......................................................................................................................................... 57
Manipur ...................................................................................................................................................58
Meghalaya .............................................................................................................................................59
Mizoram ................................................................................................................................................. 60
Nagaland .................................................................................................................................................61
Odisha .....................................................................................................................................................62
Puducherry ............................................................................................................................................63
Punjab .....................................................................................................................................................64
Rajasthan ................................................................................................................................................65
Sikkim ......................................................................................................................................................66
Tamil Nadu ............................................................................................................................................. 67
Telangana ...............................................................................................................................................68
Tripura .....................................................................................................................................................69
Uttarakhand ...........................................................................................................................................70
Uttar Pradesh .........................................................................................................................................71
West Bengal .......................................................................................................................................... 72
INDIA HIV ESTIMATES 2019
xviii
AbbreviationsAIIMS All India Institute of Medical Sciences
AIM AIDS Impact Module
ANC Antenatal Care
CI Confidence Interval
CLHIV Children Living with HIV
CST Care, Support and Treatment
DAPCU District AIDS Prevention Control Unit
EPP Estimation and Projection Package
FSW Female Sex Worker
HSS HIV Sentinel Surveillance
H/TG Hijra/Transgender
IBBS Integrated Biological and Behavioural Surveillance
ICMR Indian Council of Medical Research
ICTC Integrated Counselling and Testing Centre
IDU Injecting Drug User
IIPS International Institute for Population Sciences
MoHFW Ministry of Health and Family Welfare
MSM Men Having Sex with Men
NACO National AIDS Control Organization
INDIA HIV ESTIMATES 2019
xix
NACP National AIDS Control Programme
NARI National AIDS Research Institute
NFHS National Family Health Survey
NICED National Institute of Cholera and Enteric Diseases
NIE National Institute of Epidemiology
NIMS National Institute of Medical Statistics
NWG National Working Group
PGIMER Postgraduate Institute of Medical Education and Research
PLHIV People Living with HIV
PMTCT Prevention of Mother-to-Child Transmission
RIMS Regional Institute of Medical Sciences
SDG Sustainable Development Goal
TRG Technical Resource Group
UNAIDS Joint United Nations Programme on HIV/AIDS
UT Union Territory
WHO World Health Organization
INDIA HIV ESTIMATES 2019
xx
INDIA HIV ESTIMATES 2019
xxi
Executive SummaryNational AIDS Control Organization (NACO), Ministry of Health and Family Welfare (MoHFW), Government of India undertakes model-based biennial HIV estimations in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Medical Statistics (NIMS). The objective of this biennial exercise is to provide an update on the current status of the HIV epidemic in the country/State/Union Territory (UT)/district on key epidemiological parameters of HIV prevalence, new infections and AIDS-related mortality. HIV estimations also provide the need for the elimination of mother-to-child transmission of HIV. HIV Estimations 2019 is the report on the latest round in the series of HIV Estimations process.
HIV estimation employs the Joint United Nations Programme on HIV/AIDS (UNAIDS)-supported Spectrum tool as an ongoing activity of the National AIDS Control Programme (NACP). Spectrum version 5.80 has been used for the 2019 round of HIV Estimations. This tool is developed under the technical guidance of the UNAIDS Reference Group on Estimates, Modelling, and Projections. The use of this tool has not only standardized the method but also facilitated comparison of the State/UT or national estimates with the UNAIDS-published global, regional and country estimates.
Like all previous rounds, the State/UT models in this round are improved over previous
rounds in terms of data inputs, approach to handling the survey data as well as assumptions of various epidemiological parameters. Improvements included updating fertility rates and age distribution of fertility and updating programmatic and epidemiological data, including use of State-specific HIV prevalence data (95% confidence interval [CI]) from the latest round of National Family Health Survey (NFHS)-IV to calibrate the epidemic curve. For the first time, the HIV Estimations 2019 exercise has also used data on routine HIV testing of pregnant women under NACP to inform the epidemiological curve. Further, the ratio of female to male incidence for 15–49 years was also updated using NFHS-IV data. In view of these improvements, results from HIV Estimations 2019 cannot be compared with any of the previous rounds of estimations and will be considered as replacements for all previous estimations concerning the level and trends of the HIV epidemic as well as programmatic needs.
In 2019 at the national level, there were an estimated 23.49 lakh (17.98 lakh – 30.98 lakh) people living with HIV (PLHIV), with an adult (15–49 years) HIV prevalence of 0.22% (0.17–0.29%). Children living with HIV (CLHIV) comprised 3.4% of the total PLHIV estimates. HIV-infected women (15+ years) constituted around 44% of the total estimated 15+ years PLHIV. There were 69.22 thousand (37.03 thousand – 121.50 thousand ) new HIV
INDIA HIV ESTIMATES 2019
xxii
infections in 2019 which has declined by 37% since 2010 and by 86% since reaching the peak in 1997. There were 58.96 thousand (33.61 thousand – 102.16 thousand) AIDS-related deaths in 2019, which has declined by 66% since 2010 and by 78% since attaining peak mortality in 2005. HIV incidence was estimated at 0.05 per 1,000 uninfected population in 2019. Around 20.52 thousand (14.98 thousand – 28.13 thousand) pregnant women were estimated to be in need of prevention of mother-to-child transmission (PMTCT).
Mizoram was estimated to have the highest adult HIV prevalence (2.32% [1.85–2.84%]), followed by Nagaland (1.45% [1.15–1.78%]) and Manipur (1.18% [0.97–1.46%]). Other States/UTs with an estimated adult HIV prevalence that was higher than the national average included Andhra Pradesh (0.69% [0.54–0.89%]), Meghalaya (0.54% [0.46–0.63%]), Telangana (0.49% [0.35–0.66%]), Karnataka (0.47% [0.37–0.59%]), Delhi (0.41% [0.33–0.50%]), Maharashtra (0.36% [0.25–0.53%]), Puducherry (0.35% [0.20–0.58%]), Goa (0.27% [0.19–0.46%]), Punjab (0.27% [0.22–0.35%]), Dadra and Nagar Haveli (0.23% [0.14–0.37%]), and Tamil Nadu (0.23% [0.16–0.29%]).
Maharashtra had the highest estimated number of PLHIV (3.96 lakh), followed by Andhra Pradesh (3.14 lakh), Karnataka (2.69 lakh), Uttar Pradesh (1.61 lakh), Telangana (1.58 lakh), Tamil Nadu (1.55 lakh), Bihar (1.34 lakh) and Gujarat (1.04 lakh). Together, these eight States constituted 72% of the total PLHIV estimates in the country. West Bengal, Delhi, Punjab, Rajasthan, Madhya Pradesh, Odisha and Haryana contributed another 18% of the total PLHIV size.
HIV incidence per 1,000 uninfected population in 2019 was estimated to be the highest in Mizoram (1.18 per 1,000 uninfected population), followed by Nagaland (0.73) and Manipur (0.34). Other States estimated to have HIV incidence per 1,000 uninfected population above the national average of 0.05 were Meghalaya (0.23), Delhi (0.15), Tripura (0.11), Chhattisgarh (0.10), Haryana (0.09), Punjab (0.08), Telangana (0.08), Bihar (0.07) and Maharashtra (0.07).The incidence rate among high-risk groups (HRGs) was higher than the total incidence estimates.
Maharashtra was estimated to have the highest number of new HIV infections in 2019 (8.54 thousand), followed by Bihar (8.04 thousand), Uttar Pradesh (6.72 thousand), West Bengal (3.97 thousand), Gujarat (3.37 thousand) and Delhi (2.99 thousand). Madhya Pradesh, Chhattisgarh, Andhra Pradesh, Telangana, Rajasthan, Tamil Nadu, Haryana, Punjab and Odisha were the other States with the estimated annual new HIV infections each ranging between 2,000 and 3,000 in 2019. Together, these 15 States accounted for 83% of the total new HIV infections in the country.
Nationally, the annual new HIV infections has decreased by 37% since 2010. The decline in annual new HIV infections has been noted in all States/UTs except for Tripura, Arunachal Pradesh, Chhattisgarh and Chandigarh. The highest decline has been noted in Karnataka (75%), followed by Himachal Pradesh (74%) and Andhra Pradesh (65%). Annual new HIV infections are estimated to have increased in Tripura, Arunachal Pradesh and Chhattisgarh; while they have stabilized in Mizoram and West Bengal.
INDIA HIV ESTIMATES 2019
xxiii
AIDS mortality was estimated at 4.43 per 100,000 population in 2019 at the national level, which peaked at around 25 during 2004/05 and then continued to decline. State/UT-wise, AIDS mortality per 100,000 population was estimated to be the highest in Manipur (36.86), followed by Mizoram (28.34), Nagaland (26.20), Andhra Pradesh (21.76), Puducherry (15.33), Meghalaya (11.08) and Telangana (10.79). In addition, Karnataka (9.72), Goa (9.68), Maharashtra (7.81), Haryana (6.83), Chandigarh (5.74), Chhattisgarh (5.25) and Delhi (5.21) were the other States/UTs where AIDS mortality was estimated to be at 5 per 100,000 population or higher.
Nationally, there were an estimated 20.52 thousand (14.98 thousand – 28.13 thousand) pregnant women who would require antiretroviral treatment (ART) to prevent mother-to-child transmission of HIV. States
accounting for the highest need were Maharashtra (14.7% of the total PMTCT needs), Bihar (12.3%) and Uttar Pradesh (10.8%), Karnataka (6.8%), Andhra Pradesh (6.8%), Telangana (5%), Gujarat (4.8%), Rajasthan (4.2%), Tamil Nadu (4.1%) and West Bengal (3.3%).
The HIV Estimations 2019 report reiterates that while the country is on track in achieving the reduction in AIDS-related deaths at the national level and also in majority of the States/UTs, fast-tracking the progress to achieve targets for reduction in new HIV infections remains a priority. Further, district-level disaggregation of these estimates will provide a more granular understanding of the epidemic in these States/UTs and may further augment the process of prioritization at the sub-national level and also strengthen the AIDS response at the local level.
INDIA HIV ESTIMATES 2019
xxiv
INDIA HIV ESTIMATES 2019
1
HIV epidemic monitoring has been a vital component of strategic information activities under the NACP since its inception. This is done through a robust institutional arrangement inclusive of Technical Resource Group (TRG) on HIV Surveillance and Estimation, national and regional institutes, State AIDS Control Societies, and a network of laboratories for testing and re-testing of blood specimen (see Figure 1). Under this institutional arrangement, ICMR–NIMS is the nodal institute for HIV Estimations.
Model-based HIV estimation is undertaken biennially under the NACP as one of the fundamental epidemic monitoring activities.The objective of this biennial exercise is to provide an update on the current status of the HIV epidemic in the country/State/UT/district on key epidemiological parameters such as HIV prevalence, new infections and AIDS-related mortality. Estimations on the need for measures to eliminate mother-to-child transmission of HIV are also provided.
Modelled HIV estimations are critically needed in a country like India as it is not possible to enumerate PLHIV by performing a census-based testing of each individual for HIV regularly. Similarly, it is not possible
to count the number of AIDS-related deaths because it will require investigations into the cause of all reported deaths. Model-based estimates with uncertainty bounds provide scientifically appropriate and programmatically acceptable information on levels and trends of the HIV epidemic, which can inform decisions related to resource allocation and planning, and an insight on the impact of the AIDS response. The first HIV estimation exercise in India was conducted in 1998, while the latest round was completed in 2017.
HIV Estimation 2019 under the NACP was done using the UNAIDS-supported Spectrum tool version 5.80. This tool is developed under the technical guidance of the UNAIDS Reference Group on Estimates, Modelling and Projections1. Its use has not only standardized the method but also made possible the comparison of the State/UT or national estimates with the UNAIDS-published global, regional and country estimates.
It is important to note that results from HIV Estimations 2019 cannot be compared with the previous rounds. As a part of the process, State/UT-wise models are prepared for every
1 http://www.epidem.org/
01 Background
INDIA HIV ESTIMATES 2019
2
round of estimations using the latest version of the Spectrum tool. The State/UT models may diff er from one round to the next for two reasons. First, improvements are incorporated into the UNAIDS-supported Spectrum model itself based on the latest available evidence and understanding of the epidemic as well as of the impact of the programmatic interventions. Second, new demographics, surveillance, survey and programme data are incorporated into each of the State/UT models. Such improvements
can change the trends of HIV prevalence and incidence over time. Because of these augmentations to the model and addition of new data to create the estimates for each round, the results from previous rounds of estimates cannot be compared to the results of the current round, and only findings from the current round of estimates shall be used for all references. This is as per the UNAIDS recommendations regarding the comparison of the latest estimates with previously published estimates2.
2 Joint United Nations Programme on HIV/AIDS (UNAIDS). Methods for deriving UNAIDS estimates. Geneva: UNAIDS; 2016
Figure 1: Institutional Framework for HIV Surveillance and Estimation under NACP
NATIONAL AIDS CONTROL ORGANISATIONTechnical Resource Group on Survellance & Estimation
AIIMS ICMR-NIMS
Nodal Agency: HIV Sentinel Surveillance Coordination and Supervision, Analysis and Documentation
Nodal Agency: HIV Estimation – PLHIV, New Infections and AIDS-related Mortality
CENTRAL TEAM REGIONAL INSTITUTIONS REFERENCE LABORATORIES
Quality Control on Testing Labs
Supervision
North ZonePGIMER
Chandigarh(5 States/UTs)
Central ZoneAIIMS
New Delhi(5 States)
West ZoneICMR–NARI
Pune(7 States/UTs)
South ZoneICMR–NIEChennai
(7 States/UTs)
East ZoneICMR–NICED
Kolkata(6 States/UTs)
North East ZoneRIMS
Imphal(5 States)
Technical Validation of New Sites, Training, Monitoring, Supervision & Data Entry; Technical Support & Guidance to SACS in Planning,
Implementation, Troubleshooting & Analysis
STATE AIDS CONTROL SOCIETY STATE SURVEILLANCE TEAMS
Primary Implementing Agency in the State Training and Supervision
DAPCU Testing Laboratories
Sentinel Sites
Coordination
Nodal Agency: Policy, Strategy & Plan
INDIA HIV ESTIMATES 2019
3
02 Process
The process of HIV Estimations 2019 was initiated vide NACO’s off ice order no. T-11020/08/2019-NACO (Surveillance) dated 21.08.2019. It identified the National Working Group (NWG) and defined the conceptual framework and activity timeline matrix with the objective of providing the latest epidemiological estimates at the national, State and district levels (see Figure 2). It was decided that the district-level estimations will be done after publications of State/UT-results for HIV Estimations 2019.
The NWG for HIV Estimation 2019 is chaired by the Director, ICMR–NIMS, New Delhi and co-chaired by the Assistant Director General – Strategic Information, NACO. It has members with expertise in demography, epidemiology, statistics, etc. coming from national and regional institutes for HIV Surveillance and Estimation, UNAIDS, World Health Organization (WHO), Center for Disease Control, independent technical experts and from NACO. An expert from the International Institute for Population
Sciences (IIPS), the nodal organization for implementing the NFHS, is also represented in the NWG. The composition and terms of reference (ToR) of the NWG are placed at annexure 1.
As a part of the process, NACO organized a four-day capacity building-cum-expert consultation workshop on HIV Estimations 2019 for national, regional, and State/UT stakeholders on 27–30 August 2019 with support from UNAIDS. Jointly, ICMR–NIMS and NACO convened three meetings of NWG during which the data inputs, adopted approaches and model results were reviewed and validated. After the recommendations from the NWG, the methods and results for HIV Estimations 2019 were presented to the TRG on HIV Surveillance and Estimations for their review and recommendations. In continuation, this technical report presents the method and results from HIV Estimations 2019.
INDIA HIV ESTIMATES 2019
4
Figure 2: Process of HIV Estimations 2019
2. Constitution of
NWG
3. Capacity
building on latest Spectrum
tools
4. Inputs data
compilation, review and finalization
5. Creation, review and finalization
of State/UT-wise projections
6. Multiple round of internal reviews & consultation
with international experts
7. Presentation of findings to
TRG
8. Preparation, release and
dissemination of HIV Estimations
2019 report
1. Planning for
implementation of HIV
Estimations 2019
INDIA HIV ESTIMATES 2019
5
3.1 OverviewHIV Estimations 2019 used the UNAIDS-supported Spectrum version 5.8, which was the latest version available during the implementation period. The final State/UT model from HIV Estimations 2017 was used as the starting point to develop the State/UT models for HIV Estimations 2019.
Spectrum is a suite of models available as analytical tools for policymakers for informed decision- making. Two of its modules, namely the DemProj module and the AIDS Impact Module (AIM), are used for HIV Estimations.3
DemProj projects the demographics by age and sex for the given locality using inputs on birth rates (fertility), death rates (mortality), and migration. Demographics inputs include population size, level, and trends of fertility and mortality, sex ratio at birth and net migration. Demographics data are entered by age and sex to inform the projections. The population projection is set from 1981 to 2026. The first case of AIDS was detected
in India in 1986 and accordingly, 1981 has been chosen as the base year under the assumption that the epidemic must have started earlier. State-specific age and sex population projections have been made and subsequently used as input in the model after cross-matching them with Census results for 1991, 2001, and 2011 to ensure consistency.
AIM accounts for the programme statistics, population sub-groups among 15–49 years with their size, HIV prevalence and sex-age pattern of HIV incidence. It factors in all the epidemiological programme-related inputs such as setting up of the CD4 -based eligibility for treatment, coverage of PMTCT and ART programme. Then the size and HIV prevalence among various population groups including antenatal clinic attendees and population groups at high risk of HIV infection, such as female sex workers (FSW), men having sex with men (MSM), hijra/transgender (H/TG) people and injecting drug users (IDUs) are inputted in the module. The next step in AIM is curve fitting. HIV estimations in India has done the fitting of
3 Stover J, Brown T, Marston M. Updates to the Spectrum/Estimation and Projection Package (EPP) model to estimate HIV trends for adults and children. Sex Transm Infect. 2012 Dec 1;88(Suppl 2): i11-6
03 Method and Data Inputs
INDIA HIV ESTIMATES 2019
6
the epidemic in the past using ‘Estimation and Projection Package (EPP)-Classic’ model, which has also been used during HIV Estimations 2019. After generating the epidemic curves, the sex-age pattern for incidence is inputted and results are then produced in the AIM. Plausible values of range for each output indicator are then generated through uncertainty analysis tool of AIM by defining the standard deviation for the given indicator. Figure 3 depicts the conceptual framework for HIV estimations using the Spectrum tool.
3.2 Spectrum Version 5.8The Spectrum tool continues to improve under the technical guidance of the UNAIDS Reference Group on Estimates, Modelling and Projections. The latest updates to the Spectrum/AIM model have been described elsewhere.4,5 The update has been made
for the assumptions regarding mother-to-child transmission rates based on the additional evidence available for peripartum and postpartum transmission; however, diff erences between 5.63 version and 5.80 version were in the decimal-point range (Table 1).
3.3 Key Methodological/Data Updates in the State/Union Territory ModelA. Demographics:
a. Total fertility rate and age distribution of fertility were updated using the latest evidence from the Sample Registration Survey and National Family Health Surveys.
4 Stover J, Glaubius R, Mofenson L, Dugdale CM, Davies MA, Patten G, Yiannoutsos C. Updates to the Spectrum/AIM model for estimating key HIV indicators at national and subnational levels.
5 Case KK, Johnson LF, Mahy M, Marsh K, Supervie V, Eaton JW. Summarizing the results and methods of the 2019 Joint United Nations Programme on HIV/AIDS HIV estimates.
Figure 3: HIV Estimations Conceptual Framework
Demographic Data
Programme Statistics
Epidemic Patterns
Surveillance and Survey Data
Demographic and Epidemic Calculations
• Mother-to-child transmission
• Child model
• Adult model
Prevalence / incidence trend
(EPP)
Results
• Number of PLHIV
• New infections
• AIDS deaths
• Need for ART
• Need for PMTCT
INDIA HIV ESTIMATES 2019
7
Table 1: Peripartum and Breastfeeding Transmission Rates by Antiretroviral Regimen
Regimen
Spectrum v5.8 Spectrum v5.63
PerinatalBreastfeeding
(per month) PerinatalBreastfeeding
(per month)< 350 ≥ 350 < 350 ≥ 350
No prophylaxis
Existing infections
CD4 < 200 37 0.89 37 0.81
CD4 200–350 27 0.81 27 0.81
CD4 > 350 15 0.51 15 0.51
Incident infections 18.1 26.9 26.9 18.2 26.9 26.9
Regimen options
Single dose nevirapine 7.5 0.99 0.4 8.9 0.78 0.51
WHO 2006 dual ARV regimen 2.2 0.18 0.18 4.1 0.78 0.51
Option A 4.1 0.2 4.1 0.2
Option B 1.9 0.13 1.9 0.13
ART
Started before pregnancy 0.26 0.023 0.21 0.013
Started during pregnancy > 4 weeks 1.4 0.11 1.9 0.13
Started during pregnancy < 4 weeks 8.2 0.2 7.6 0.2
B. Programme Statistics:
a. The programme data on PMTCT and ART (adult and paediatric) coverage was updated for the years 2017, 2018, and 2019.
b. To project the coverage for the period 2020–2026, the most recent trend in coverage scale-up (the last 1–2 years), as observed in the programme, was used.
c. For Chandigarh and Delhi, data on PLHIV on ART was disaggregated by State of residence and then adjusted accordingly.
d. The size of adult and child PLHIV on ART was reconciled using
data on the date of birth of PLHIV on ART using Integrated Management System data.
C. Epidemic Configuration:
a. In select States with no HRG population in the epidemic configuration in 2017 round of estimation because of limited trend prevalence data points, HRG sub-population was added in the epidemic configuration. A ratio of antenatal care (ANC) prevalence point vis-à-vis HRG prevalence in the corresponding year for the State was created using local evidence. The ratio
INDIA HIV ESTIMATES 2019
8
was applied to the time series of ANC surveillance data to generate the HRG prevalence time series data points.
D. Surveillance Data:
a. Surveillance data points from the 2019 round of ANC HIV Sentinel Surveillance (HSS) were used to update the general population data points.
b. For HRG, the last improvements for the year 2017 were used in the absence of any new surveillance data for the group
c. Routine-testing data from stand-alone integrated counselling and testing centre (ICTC) of pregnant women was inputted for the period 2010–2018 as additional data points to inform general population curves.
d. For States with two rounds of National Family Health Survey on HIV prevalence (Andhra Pradesh, Maharashtra, Karnataka, Tamil Nadu, Telangana, Uttar Pradesh, Manipur and Nagaland [for Nagaland, findings from a special study from 2006 was also referred as per previous estimations rounds]), the NFHS data points were inputted for the general population.
E. Epidemic Curves Fitting and Calibration:
a. For HRG population, epidemic curve fitting was done using HRG HSS data.
b. For general population, ANC surveillance data and routine stand-alone ICTC data were used to inform the curve fitting for all States.
c. In States with two HIV prevalence data points from the community-based survey, the same was used in curve fitting.
d. HIV prevalence for HRG population was calibrated using HIV prevalence from Integrated Biological and Behavioural Surveillance (IBBS).
e. HIV prevalence for the general population was calibrated using HIV prevalence (95% CI) from NFHS-IV.
F. Sex Ratio:
a. The ratio of female to male incidences for 15–49 years age group was updated using NFHS-IV data.
INDIA HIV ESTIMATES 2019
9
The results from HIV Estimations 2019 on level and trends of prevalence, incidence, AIDS-related deaths, and PMTCT needs have been provided in this report. It is important to reiterate that these results, generated using the most updated Spectrum tool and having the most recent data inputs, replace the results from previous rounds of estimates. For all comparisons, the time trend data, as provided through HIV Estimations 2019, shall only be used until the data from the next round of estimation is made available. This is in accordance with the recommendations of the UNAIDS, Geneva, stating that results from previous years cannot be compared with the results from this year.6
The report provides the national as well as State/UT-wise estimates. For a visual comparison, trends on epidemiological estimates have been presented for six specific regions depicting each State/UT in the region. The grouping has been kept
the same as that used in the National Family Health Survey for consistency.7 These groups are:
(i) North: Chandigarh (CH), Delhi (DL), Haryana (HR), Himachal Pradesh (HP), Jammu & Kashmir (JK),8 Punjab (PJ), Rajasthan (RJ) and Uttarakhand (UK)
(ii) Central: Chhattisgarh (CG), Madhya Pradesh (MP) and Uttar Pradesh (UP)
(iii) East: Bihar (BH), Jharkhand (JH), Odisha (OD), West Bengal (WB)
(iv) Northeast: Arunachal Pradesh (AR), Assam (AS), Manipur (MN), Meghalaya (MG), Mizoram (MZ), Nagaland (NG), Sikkim (SK) and Tripura (TR)
(v) West: Dadra & Nagar Haveli (DNH), Daman & Diu (DD), Goa (GO), Gujarat (GJ), Maharashtra (MH)
6 UNAIDS HIV data and estimates. UNAIDS Geneva. Available at https://www.unaids.org/en/dataanalysis/knowyourresponse/HIVdata_estimates and accessed on 26.02.2020
7 http://rchiips.org/NFHS/NFHS-4Reports/India.pdf8 Refer to formar State of Jammu & Kashmir including Ladakh before its reorganization under Jammu and Kashmir Reorganization
Act, 2019
04 Results
INDIA HIV ESTIMATES 2019
10
(vi) South: Andaman & Nicobar Islands (AN), Andhra Pradesh (AP), Karnataka (KA), Kerala (KE), Puducherry (PO), Tamil Nadu (TN) and Telangana (TL)
4.1 Overview Nationally, there were an estimated 23.49 lakh (17.98 lakh – 30.98 lakh) PLHIV in 2019, with an adult (15–49 years) HIV prevalence of 0.22% (0.17–0.29%). This includes around 79 thousand CLHIV accounting for 3.4% of the total PLHIV estimates. There were 9.94 lakh women living with HIV (15+ years) constituting around 44% of the total estimated 15+ years PLHIV. There were 69.22 thousand (37.03 thousand – 121.50 thousand) new HIV infections in 2019, which has declined by 37% since 2010 and by 86% since attaining the peak in 1997. There were 58.96 thousand (33.61 thousand – 102.16 thousand) AIDS-related deaths in the year
2019, which has declined by 66% since 2010 and by 78% since attaining its peak in 2005. HIV incidence was estimated at 0.05 per 1,000 uninfected population in 2019. Around 20.52 thousand (14.98 thousand – 28.13 thousand) pregnant women were estimated to be in need of PMTCT (see Table 2).
4.2 Adult (15–49 years) HIV Prevalence Overall, the estimated adult (15–49 years) HIV prevalence trend has been declining in India since the epidemic’s peak in the year 2000 and has been stabilizing in recent years. The estimate for this indicator was 0.22% (0.17–0.29%) in 2019 (see Figure 4). In the same year, HIV prevalence among adult males (15–49 years) was estimated at 0.24% (0.18–0.32%) and among adult females at 0.20% (0.15–0.26%).
Figure 4: Trend of Adult HIV Prevalence in India, 1981–2019 (in %)
1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015 2017 2019
2.0
1.5
1.0
0.5
0.0
INDIA HIV ESTIMATES 2019
11
Table 2: Status of the HIV/AIDS Epidemic in 2019
Adult (15–49 years) HIV prevalence (%) Total 0.22 [0.17–0.29]
Male 0.24 [0.18–0.32]
Female 0.20 [0.15–0.26]
Number of people living with HIV (lakh*) Total 23.49 [17.98–30.98]
Adults (15+ years) 22.70 [17.37–29.97]
Female(15+ years) 9.94 [7.61–13.00]
Children (<15 years) 0.79 [0.58–1.05]
HIV incidence per 1,000 uninfected population Total 0.05 [0.03–0.09]
Male 0.06 [0.03–0.10]
Female 0.05 [0.02–0.08]
New HIV infections (thousand) Total 69.22 [37.03–121.50]
Adults (15+ years) 65.24 [34.45–115.51]
Female (15+ years) 27.58 [14.45–49.53]
Children (<15 years) 3.98 [2.49–6.11]
Decline in new HIV infections since 2010 (%) Total 37.4
Adults (15+ years) 33.9
Female (15+ years) 32.3
Children (<15 years) 66.1
AIDS-related deaths (thousand) Total 58.96 [33.61–102.16]
Adults (15+ years) 55.40 [31.55–96.58]
Female (15+ years) 16.76 [8.46–31.73]
Children (<15 years) 3.57 [1.94–5.74]
Decline in AIDS-related deaths since 2010 (%) Total 66.1
Adults (15+ years) 66.1
Female (15+ years) 73.7
Children (<15 years) 65.3
PMTCT needs (thousand) Total 20.52 [14.98–28.13]
* Lakh = 100,000
INDIA HIV ESTIMATES 2019
12
At the sub-national level, three States with the highest adult HIV prevalence were from the north-eastern part of the country, namely Mizoram (2.32% [1.85–2.84%]), Nagaland (1.45% [1.15–1.78%]), and Manipur (1.18% [0.97–1.46%]) (see Figure 5). Other States/UTs estimated to have adult HIV prevalence higher than the national average were Andhra Pradesh (0.69% [0.54–0.89%]), Meghalaya (0.54% [0.46–0.63%]), Telangana (0.49% [0.35–0.66%]), Karnataka (0.47% [0.37–0.59%]), Delhi (0.41% [0.33–0.50%]), Maharashtra (0.36% [0.25–0.53%]), Puducherry (0.35% [0.20–0.58%]), Goa (0.27% [0.19–0.46%]), Punjab (0.27% [0.22–0.35%]), Dadra and Nagar Haveli (0.23% [0.14–0.37%]), and Tamil Nadu (0.23% [0.16–0.29%]).
A decline in HIV prevalence, similar to the national trend, has been noted in the southern States of Andhra Pradesh, Karnataka, Tamil Nadu and Telangana, the western States of Maharashtra, Goa and Gujarat, the northern States of Punjab and Haryana, and the north-eastern State of Manipur (Figure 6). In the rest of the States/UTs, HIV prevalence appeared to range from
being stable to rising. Particularly, adult prevalence has been rising in Mizoram and was stable in Nagaland at a very high level. The rising HIV prevalence was noted in the rest of the north-eastern States.
4.3 Number of People Living with HIVNationally, there were an estimated 23.49 lakh (17.98 lakh – 30.98 lakh) PLHIV in 2019. Maharashtra was estimated to have the highest number of PLHIV (3.96 lakh), followed by Andhra Pradesh (3.14 lakh), Karnataka (2.69 lakh), Uttar Pradesh (1.61 lakh), Telangana (1.58 lakh), Tamil Nadu (1.55 lakh), Bihar (1.34 lakh) and Gujarat (1.04 lakh) (see Figure 7). Together, these eight States constituted 72% of the total PLHIV estimates in the country. The States of West Bengal, Delhi, Punjab, Rajasthan, Madhya Pradesh, Odisha and Haryana contributed another 18% of the total PLHIV size. Overall, 90% of PLHIV estimates were from these 15 States (see Figure 8).
Figure 5: Estimates of Adult HIV Prevalence by State/UT, 2019 (in %)
2.32
0.69
0.54
0.49
0.47
0.41
0.36
0.35
0.27
0.27
0.23
0.22
0.21
0.20
0.20
0.19
0.18
0.17
0.13
0.12
0.11
0.10
0.10
0.10
0.0
90.
09
0.0
90.
08
0.07
0.0
60.
06
0.14
0.140.23
1.45
1.18
Biha
r
Ass
amKe
rala
Sikk
im
Miz
oram
Nag
alan
dM
anip
urA
ndhr
a Pr
ades
h
Mah
aras
htra
Dad
ra &
Nag
ar
Pudu
cher
ry
Meg
hala
yaTe
lang
ana
Karn
atak
a
Punj
ab
Tam
il N
adu
Har
yana
Guj
arat
Odi
sha
Trip
ura
Chh
attis
garh
Cha
ndig
arh
Dam
an &
Diu
Him
acha
l Pra
desh
Raja
stha
nM
adhy
a Pr
ades
hU
ttar
Pra
desh
Wes
t Ben
gal
Jhar
khan
d
Aru
nach
al P
rade
shJa
mm
u &
Kas
hmir
And
aman
& N
icob
arU
ttar
akha
nd
Indi
a
Del
hi
Goa
3.00
2.00
1.00
0.00
INDIA HIV ESTIMATES 2019
13
AN - Andaman and Nicobar Islands, AP - Andhra Pradesh, AR - Arunachal Pradesh, AS - Assam, BH - Bihar, CG - Chhattisgarh, CH - Chandigarh, DD - Daman and Diu, DL - Delhi, DNH - Dadra and Nagar Haveli, GJ - Gujarat, GO - Goa, HP - Himachal Pradesh, HR - Haryana, JH - Jharkhand, JK - Jammu and Kashmir, KA - Karnataka, KE - Kerala, MG - Meghalaya, MH - Maharashtra, MN - Manipur, MP - Madhya Pradesh, MZ - Mizoram, NG - Nagaland, OD - Odisha, PJ - Punjab, PO - Pondicherry, RJ - Rajasthan, SK - Sikkim, TL – Telangana, TN - Tamil Nadu, TR - Tripura, UK - Uttarakhand, UP - Uttar Pradesh, WB - West Bengal
Figure 6: Trend of Adult HIV Prevalence in States/UTs, 1981–2019 (in %)
MN MZ NG
4.00
3.00
2.00
1.00
0.00
1981
1984
1987
1990
19 9
3
1996
1999
200
2
200
5
200
8
2011
2014
2017
2019
AR AS SKMG TR
1981
1984
1987
1990
19 9
3
1996
1999
200
2
200
5
200
8
2011
2014
2017
2019
0.600.500.400.300.200.10
0.00
BH JH WBOD
1981
1984
1987
1990
19 9
3
1996
1999
200
2
200
5
200
8
2011
2014
2017
2019
0.25
0.20
0.15
0.10
0.05
0.00
CG MP UP
1981
1984
1987
1990
19 9
3
1996
1999
200
2
200
5
200
8
2011
2014
2017
2019
0.40
0.30
0.20
0.10
0.00
HP HR PJJK RJ UK CHDL
0.50
0.40
0.30
0.20
0.10
0.00
1981
1984
1987
1990
19 9
3
1996
1999
200
2
200
5
200
8
2011
2014
2017
2019
1981
1984
1987
1990
19 9
3
1996
1999
200
2
200
5
200
8
2011
2014
2017
2019
0.300.250.200.150.100.050.00
GJ DNH DD
3.002.502.001.501.000.500.00
1981
1984
1987
1990
19 9
3
1996
1999
200
2
200
5
200
8
2011
2014
2017
2019
AP KA TNKE AN PO TL
1981
1984
1987
1990
19 9
3
1996
1999
200
2
200
5
200
8
2011
2014
2017
2019
2.50
2.00
1.50
1.00
0.50
0.00
GO MH
INDIA HIV ESTIMATES 2019
14
Figure 7: Estimates of PLHIV by State/UT, 2019 (in lakh)
Figure 8: Distribution of PLHIV by State/UT, 2019 (in %)
Andhra Pradesh, 13
Maharashtra, 17
Telangana, 7
Karnataka, 11
Punjab, 3
Tamil Nadu, 7
Haryana, 2
Rest 10
Gujarat, 4
Odisha, 2
Bihar, 6
Rajasthan, 3
Madhya Pradesh, 3
Uttar Pradesh, 7
West Bengal, 3
Delhi, 3
3.96
3.14
2.69
1.61
1.58
1.55
1.34
0.74
0.68
0.66
0.45
0.43
0.29
0.24
0.23
0.20
0.11
0.11
0.07
0.0
60.
05
0.0
50.
03
0.0
20.
01
0.0
00.
00
0.0
00.
01
0.21
0.230.
490.59
0.631.0
4
Miz
oram
Nag
alan
d
Man
ipur
And
hra
Prad
esh
Mah
aras
htra
Dad
ra &
Nag
ar
Pudu
cher
ry
Meg
hala
ya
Tela
ngan
a
Karn
atak
a
Punj
ab
Tam
il N
adu
Har
yana
Guj
arat
Odi
sha
Trip
ura
Biha
r
Chh
attis
garh
Cha
ndig
arh
Dam
an &
Diu
Him
acha
l Pra
desh
Raja
stha
nM
adhy
a Pr
ades
h
Utt
ar P
rade
sh
Wes
t Ben
gal
Jhar
khan
d
Ass
am
Kera
la
Sikk
im
Aru
nach
al P
rade
sh
Jam
mu
& K
ashm
ir
And
aman
& N
icob
ar
Utt
arak
hand
Del
hi
Goa
5.0
4.0
3.0
2.0
1.0
0.0
INDIA HIV ESTIMATES 2019
15
4.4 HIV IncidenceNationally, HIV incidence was estimated at 0.05 per 1,000 uninfected population in 2019. It has declined from 0.54 in 1995 to 0.05 in 2019 (see Figure 9). State/UT-wise, incidence per 1,000 uninfected population was estimated to be the highest in the three north-eastern States of Mizoram (1.18 per 1,000 uninfected population), Nagaland (0.73) and Manipur (0.34) in 2019 (see Figure 10). Other States
estimated to have HIV incidence per 1,000 uninfected population above the national average of 0.05 were Meghalaya (0.23), Delhi (0.15), Tripura (0.11), Chhattisgarh (0.10), Haryana (0.09), Punjab (0.08), Telangana (0.08), Bihar (0.07) and Maharashtra (0.07).
Similar to the national trend, HIV incidence has declined in most of the States/UTs during the period (Figure 11). HIV incidence has been estimated to be increasing in the State of Tripura.
Figure 9: Trend of HIV Incidence in India, 1990–2019 (per 1,000 uninfected population)
Figure 10: HIV Incidence by State/UT, 2019 (per 1,000 uninfected population)
1990 1991
1992
1993
1994
1995
1996
1997
1998
1999
200
0
200
1
200
2
200
3
2004
200
5
200
6
2007
200
820
09
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
1.5
1.0
0.5
0.0
And
hra
Prad
esh
Miz
oram
Nag
alan
dM
anip
urM
egha
laya
Dad
ra &
Nag
arPu
duch
erry
Del
hiTr
ipur
a
Cha
ndig
arh
Har
yana
Chh
attis
garh
Odi
sha
Raja
stha
n
Mad
hya
Prad
esh
Punj
abTe
lang
ana
Biha
rD
aman
& D
iuM
ahar
asht
ra
Guj
arat
Indi
a
Tam
il N
adu
Him
acha
l Pra
desh
Aru
nach
al P
rade
sh
Wes
t Ben
gal
Utt
arak
hand
Jhar
khan
d
Ass
am
Kera
la
Sikk
im
Jam
mu
& K
ashm
ir
And
aman
& N
icob
ar
Utt
ar P
rade
shKa
rnat
aka
Goa
1.18
0.73
0.34
0.17
0.16
0.15
0.11
0.10
0.0
90.
08
0.0
80.
08
0.07
0.07
0.07
0.0
50.
05
0.0
50.
05
0.0
5
0.04
0.04
0.04
0.04
0.0
30.
03
0.0
30.
03
0.0
20.
02
0.0
2
0.04
0.04
0.040.0
50.23
1.5
1.0
0.5
0.0
INDIA HIV ESTIMATES 2019
16
AN - Andaman and Nicobar Islands, AP - Andhra Pradesh, AR - Arunachal Pradesh, AS - Assam, BH - Bihar, CG - Chhattisgarh, CH - Chandigarh, DD - Daman and Diu, DL - Delhi, DNH - Dadra and Nagar Haveli, GJ - Gujarat, GO - Goa, HP - Himachal Pradesh, HR - Haryana, JH - Jharkhand, JK - Jammu and Kashmir, KA - Karnataka, KE - Kerala, MG - Meghalaya, MH - Maharashtra, MN - Manipur, MP - Madhya Pradesh, MZ - Mizoram, NG - Nagaland, OD - Odisha, PJ - Punjab, PO - Pondicherry, RJ - Rajasthan, SK - Sikkim, TL – Telangana, TN - Tamil Nadu, TR - Tripura, UK - Uttarakhand, UP - Uttar Pradesh, WB - West Bengal
Figure 11: Trend of HIV Incidence in States/UTs, 1981–2019 (per 1,000 uninfected population)
BH JH WBOD
0.50
0.40
0.30
0.20
0.10
0.00
1981
1984
1987
1990
1993
1996
1999
2002
2005
2008
2011
2014
2017
2019
CG MP UP
1981
1984
1987
1990
1993
1996
1999
2002
2005
2008
2011
2014
2017
2019
0.60
0.50
0.40
0.30
0.20
0.10
0.00
HP HR PJJ&K RJ UK CHDL
1981
1984
1987
1990
1993
1996
1999
2002
2005
2008
2011
2014
2017
2019
0.60
0.50
0.40
0.30
0.20
0.10
0.00
GO MH
1981
1984
1987
1990
1993
1996
1999
2002
2005
2008
2011
2014
2017
2019
5.00
4.00
3.00
2.00
1.00
0.00
GJ DNH DD
0.400.350.300.250.200.150.100.050.00
1981
1984
1987
1990
1993
1996
1999
2002
2005
2008
2011
2014
2017
2019
AP KA TNKE AN PO TL
1981
1984
1987
1990
1993
1996
1999
2002
2005
2008
2011
2014
2017
2019
5.00
4.00
3.00
2.00
1.00
0.00
MN MZ NG
6.00
5.00
4.00
3.00
2.00
1.00
0.00
1981
1984
1987
1990
1993
1996
1999
2002
2005
2008
2011
2014
2017
2019
1981
1984
1987
1990
1993
1996
1999
2002
2005
2008
2011
2014
2017
2019
AR AS SKMG TR
0.60
0.50
0.40
0.30
0.20
0.10
0.00
INDIA HIV ESTIMATES 2019
17
The incidence rate among HRGs was higher than the total incidence estimates. In Tamil Nadu, HIV incidence among H/TG people was 0.18%, almost 18 times higher than the non-high risk population group. Among FSW, incidence (percentage) was as high as 2.12% in Meghalaya followed by 1.14% in Mizoram and Nagaland, 0.81% in Haryana, 0.67% in Maharasthra, 0.66% in Telangana and 0.63% in Karnataka. Among MSM, incidence (percentage) was estimated at 0.89% in Manipur, 0.88% in Bihar, 0.65% in Rajasthan, 0.55% in West Bengal and 0.51% in Himachal Pradesh. Among IDUs, incidence (percentage) was estimated at 16.4% in Uttar Pradesh, followed by 9.74% in Bihar, 3.71% in Maharasthra, 3.61% in Delhi, 3.51% in Haryana, 3.04% in Jharkhand, 2.80% in Mizoram, 2.47% in Chhattisgarh and 2.40% in Madhya Pradesh.
4.5 Annual New HIV InfectionsNationally, there were 69.22 thousand (37.03 thousand – 121.50 thousand) estimated new HIV infections in 2019. This translates into 190 new infections every day and eight new infections every hour.
State/UT-wise, Maharashtra was estimated to have the highest number of new HIV infections in 2019 (8.54 thousand), followed by Bihar (8.04 thousand), Uttar Pradesh (6.72 thousand), West Bengal (3.97 thousand), Gujarat (3.37 thousand) and Delhi (2.99 thousand). In addition, Madhya Pradesh, Chhattisgarh, Andhra Pradesh, Telangana, Rajasthan, Tamil Nadu, Haryana, Punjab and Odisha were the other States with estimated annual new HIV infections ranging between 2,000 and 3,000 in 2019 (see Figure 13).
Figure 12: HIV Incidence among HRG in Select States (per 1,000 uninfected population)
And
hra
Prad
esh
Aru
nach
al P
rade
sh
Karn
atak
a
Mah
aras
htra
Nag
alan
d
Utt
arak
hand
Tela
ngan
a
Odi
sha
Punj
ab
Sikk
im
Miz
oram
Meg
hala
ya
Har
yana
Del
hi
0.14 0.
30
0.28
0.81
2.12
0.63 0.67
1.14
1.14
0.22
0.16 0.24 0.30
0.66
FSW
MSM
Biha
r
Man
ipur
Guj
arat
Him
acha
l Pra
desh
Karn
atak
a
Kera
la
Mad
hya
Prad
esh
Odi
sha
Punj
ab
Raja
stha
n
Utt
ar P
rade
sh
Wes
t Ben
gal
0.88
0.89
0.28
0.51
0.27
0.18
0.16
0.46
0.14
0.65
0.27
0.55
IDU
Utt
ar P
rade
sh16
.40
Wes
t Ben
gal
1.64
Trip
ura
0.86
Tam
il N
adu
0.92
Punj
ab1.3
0
Odi
sha
1.69
Miz
oram
2.80
Mah
aras
htra
3.71
Mad
hya
Prad
esh
2.40
Chh
attis
garh
2.47
Jhar
khan
d3.
04
Har
yana
3.61
Del
hi
3.51
Biha
r9.
74
INDIA HIV ESTIMATES 2019
18
Together, these 15 States accounted for 83% of the total new HIV infections in the country.
Nationally, annual new HIV infections have decreased by 37% since 2010. The decline in annual new HIV infections has been noted in
all States/UTs except for Tripura, Arunachal Pradesh, Chhattisgarh and Chandigarh (see Figure 14). Among States/UTs, the highest decline has been noted in Karnataka (75%), followed by Himachal Pradesh (74%) and Andhra Pradesh (65%).
Figure 13: Annual New HIV Infections by State/UT, 2019 (in thousand)
8.54
3.97
3.37
2.99
2.89
2.83
2.82
2.772.82
2.62
2.62
2.37
2.17
1.57
1.55
1.37
1.33
1.30
0.96
0.80
0.49
0.45
0.32
0.26
0.16
0.07
0.07
0.07
0.0
60.
02
0.0
20.
02
0.120.
73
8.04
6.72
Miz
oram
Man
ipur
And
hra
Prad
esh
Dad
ra &
Nag
ar
Pudu
cher
ry
Meg
hala
ya
Tela
ngan
a
Karn
atak
a
Punj
ab
Tam
il N
adu
Nag
alan
d
Har
yana
Guj
arat
Odi
sha
Trip
ura
Biha
r
Chh
attis
garh
Cha
ndig
arh
Dam
an &
Diu
Him
acha
l Pra
desh
Raja
stha
n
Mad
hya
Prad
esh
Utt
ar P
rade
shW
est B
enga
l
Jhar
khan
dA
ssam
Kera
la
Sikk
im
Aru
nach
al P
rade
sh
Jam
mu
& K
ashm
ir
And
aman
& N
icob
ar
Utt
arak
hand
Del
hi
Goa
Mah
aras
htra
10.0
8.0
6.0
4.0
2.0
0.0
Figure 14: Percentage Change in Annual New HIV Infections by State/UT, 2010–2019
Miz
oram
Man
ipur
Indi
a
Meg
hala
yaTe
lang
ana
Punj
ab
Tam
il N
adu
Nag
alan
dH
arya
na
Guj
arat
Odi
sha
Trip
ura
Biha
r
Chh
attis
garh
Raja
stha
n
Mad
hya
Prad
esh
Utt
ar P
rade
sh
Wes
t Ben
gal
Cha
ndig
arh
Jhar
khan
d
Ass
amKe
rala
Sikk
im
Aru
nach
al P
rade
sh
Jam
mu
& K
ashm
ir
Utt
arak
hand
Del
hi
Goa
Mah
aras
htra
Karn
atak
a-7
5.1
-48.
7
And
hra
Prad
esh
-64.
9
-44.
4-4
4.0
-41.6
-38.
4-3
8.3
-37.4
-36.
6-3
6.0
-35.
9-3
5.2
-34.
4-2
9.1
-26.
9-2
4.8
-24.
2-2
2.7
-16.
2-1
2.3
-6.5
-0.5
0.5
6.3
6.5
62.2
264.
5
Him
acha
l Pra
desh
-73.
8
-46.
1-4
6.4
-52.
1
300.0
0.0
-300.0
INDIA HIV ESTIMATES 2019
19
4.6 AIDS-related MortalityNationally, AIDS-related mortality was estimated at 4.43 per 100,000 population in 2019, which peaked at around 25 during 2004/05 and then continued to decline (see Figure 15). State/UT-wise, AIDS-related mortality per 100,000 population was estimated to be the highest in Manipur (36.86), followed by Mizoram (28.34), Nagaland (26.20), Andhra Pradesh (21.76), Puducherry (15.33), Meghalaya (11.08) and Telangana (10.79). The other States/UTs where AIDS-related mortality was estimated to be at 5 per 100,000 population or higher were Karnataka (9.72), Goa (9.68), Maharashtra (7.81), Haryana (6.83), Chandigarh (5.74), Chhattisgarh (5.25) and Delhi (5.21) (see Figures 16 and 17).
4.7 Annual AIDS-related DeathsNationally, 58.96 thousand (33.61 thousand – 102.16 thousand) AIDS-related deaths were estimated in the year 2019. State/
UT-wise, Andhra Pradesh was estimated to have the highest number of AIDS deaths in 2019 (11.43 thousand), followed by Maharasthra (9.69 thousand), Karnataka (6.39 thousand), Telangana (4.08 thousand), Uttar Pradesh (3.87 thousand) and Tamil Nadu (3.01 thousand). In addition, Bihar, Haryana, Madhya Pradesh, Odisha, Gujarat, Chhattisgarh, Punjab, West Bengal, Delhi and Manipur were the other States with an estimated AIDS deaths ranging between 1,000 and 2,400 in 2019 (see Figure 18).
State/UT-wise, annual AIDS-related deaths were estimated to have declined from 2010 to 2019 in nearly all States/UTs excluding Meghalaya, Arunachal Pradesh, Tripura, Jammu and Kashmir, Jharkhand and Assam (see Figure 19). In Sikkim and Bihar, the trend for this indicator was almost stable, while in Delhi the decline was marginal (5%). On the other hand, AIDS-related deaths have declined by 70–80% in Karnataka, Telangana, Tamil Nadu, Maharashtra, Himachal Pradesh, West Bengal and Andhra Pradesh. The other States where AIDS-related deaths have declined by more than 50% since 2010 were Punjab, Goa, Chhattisgarh, Kerala, Madhya Pradesh, Manipur, Gujarat and Mizoram.
Figure 15: Trend of AIDS Mortality in India, 1990–2019 (per 100,000 population)
1990 1991
1992
1993
1994
1995
1996
1997
1998
1999
200
0
200
1
200
2
200
3
2004
200
5
200
6
2007
200
8
200
9
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
50
40
30
20
10
0
INDIA HIV ESTIMATES 2019
20
AN - Andaman and Nicobar Islands, AP - Andhra Pradesh, AR - Arunachal Pradesh, AS - Assam, BH - Bihar, CG - Chhattisgarh, CH - Chandigarh, DD - Daman and Diu, DL - Delhi, DNH - Dadra and Nagar Haveli, GJ - Gujarat, GO - Goa, HP - Himachal Pradesh, HR - Haryana, JH - Jharkhand, JK - Jammu and Kashmir, KA - Karnataka, KE - Kerala, MG - Meghalaya, MH - Maharashtra, MN - Manipur, MP - Madhya Pradesh, MZ - Mizoram, NG - Nagaland, OD - Odisha, PJ - Punjab, PO - Pondicherry, RJ - Rajasthan, SK - Sikkim, TL – Telangana, TN - Tamil Nadu, TR - Tripura, UK - Uttarakhand, UP - Uttar Pradesh, WB - West Bengal
Figure 16: Trend of AIDS Mortality in India, 1990–2019 (per 100,000 population)
120
100
80
60
40
20
0
1981
1984
1987
1990
1993
1996
1999
2002
2005
2008
2011
2014
2017
2019
GO MH
MN MZ NG
1981
1984
1987
1990
1993
1996
1999
2002
2005
2008
2011
2014
2017
2019
180
160
120
80
40
0
AR AS SKMG TR
14121086420
1981
1984
1987
1990
1993
1996
1999
2002
2005
2008
2011
2014
2017
2019
20
16
12
8
4
0
1981
1984
1987
1990
1993
1996
1999
2002
2005
2008
2011
2014
2017
2019
1981
1984
1987
1990
1993
1996
1999
2002
2005
2008
2011
2014
2017
2019
10
8
6
4
2
0
BH JH WBOD CG MP UP
1981
1984
1987
1990
1993
1996
1999
2002
2005
2008
2011
2014
2017
2019
20
16
12
8
4
0
HP HR PJJ&K RJ UK CHDL
14012010080604020
0
1981
1984
1987
1990
1993
1996
1999
2002
2005
2008
2011
2014
2017
2019
AP KA TNKE AN PO TL
14
12
10
8
6
4
2
0
1981
1984
1987
1990
1993
1996
1999
2002
2005
2008
2011
2014
2017
2019
GJ DNH DD
INDIA HIV ESTIMATES 2019
21
Figure 18: AIDS Deaths by State/UT, 2019 (in thousand)
Figure 17: AIDS Mortality by State/UT, 2019 (per 100,000 population)
36.8
628
.34
26.2
021
.76
15.3
311
.08
10.7
99.
729.
68
6.83
5.74
5.25
5.21
4.75
4.43
4.0
54.
01
3.88
3.08
2.37
2.23
2.04
1.89
1.71
1.67
0.93
0.96
0.97
1.14
1.17
1.40
1.67
0.641.5
0
0.46
7.81
50.0
40.0
30.0
20.0
10.0
0.0
Trip
ura
Man
ipur
Miz
oram
Indi
a
Meg
hala
yaPu
duch
erry
Tela
ngan
a
Punj
ab
Tam
il N
adu
Nag
alan
d
Har
yana
Guj
arat
Odi
sha
Biha
r
Chh
attis
garh
Cha
ndig
arh
Raja
stha
n
Mad
hya
Prad
esh
And
aman
& N
icob
ar
Dad
ra &
Nag
ar
Dam
an &
Diu
Utt
ar P
rade
sh
Wes
t Ben
gal
Jhar
khan
d
Ass
am
Kera
la
Sikk
im
Aru
nach
al P
rade
shJa
mm
u &
Kas
hmir
Utt
arak
hand
Del
hi
Goa
Mah
aras
htra
Karn
atak
a
And
hra
Prad
esh
Him
acha
l Pra
desh
Biha
r
Del
hi
Goa
Trip
ura
Man
ipur
Miz
oram
Meg
hala
ya
Pudu
cher
ry
Tela
ngan
a
Punj
ab
Tam
il N
adu
Nag
alan
d
Har
yana
Guj
arat
Odi
sha
Chh
attis
garh
Cha
ndig
arh
Raja
stha
n
Mad
hya
Prad
esh
And
aman
& N
icob
ar
Dad
ra &
Nag
arD
aman
& D
iu
Utt
ar P
rade
sh
Wes
t Ben
gal
Jhar
khan
d
Ass
am
Kera
la
Sikk
im
Aru
nach
al P
rade
sh
Jam
mu
& K
ashm
ir
Utt
arak
hand
Mah
aras
htra
Karn
atak
a
And
hra
Prad
esh
Him
acha
l Pra
desh
11.4
39.
696.
39
4.08
3.87
3.0
12.
331.9
51.8
21.7
41.5
71.4
81.4
21.3
71.1
01.0
80.
710.
570.
570.
530.
430.
360.
36
0.26
0.17
0.13
0.0
90.
07
0.0
20.
02
0.0
10.
01
0.0
0
0.0
2
0.34
20.00
15.00
10.00
5.00
0.00
INDIA HIV ESTIMATES 2019
22
4.8 Pregnant Women in Need of Prevention of Mother-to-Child Transmission ServicesNationally, there were an estimated 20.52 thousand (14.98 thousand – 28.13 thousand) pregnant women who would require ART to prevent mother-to-child transmission of HIV. States accounting for the highest need were Maharashtra (14.66% of the total PMTCT needs), Bihar (12.31%) and Uttar Pradesh
(10.78%), Karnataka (6.79%), Andhra Pradesh (6.76%), Telangana (5.02%), Gujarat (4.80%), Rajasthan (4.21%), Tamil Nadu (4.12%) and West Bengal (3.31%). States accounting for 2–3% of the total PMTCT needs each are Madhya Pradesh, Chhattisgarh, Delhi, Odisha, Punjab and Haryana. The States of Nagaland, Manipur, Jharkhand, Assam, Meghalaya and Mizoram account for 1–2% of the total PMTCT needs each while the remaining States/UTs have an estimated need of less than 1% each (see Figure 20).
Figure 19: Percentage Change in Annual AIDS-related Deaths by State/UT, 2010–2019
Trip
ura
Man
ipur
Miz
oram
Meg
hala
ya
Tela
ngan
a
Punj
ab
Tam
il N
adu
Nag
alan
d
Har
yana
Guj
arat
Odi
sha
Biha
r
Chh
attis
garh
Cha
ndig
arh
Raja
stha
n
Mad
hya
Prad
esh
And
aman
& N
icob
arD
adra
& N
agar
Dam
an &
Diu
Utt
ar P
rade
sh
Wes
t Ben
gal
Jhar
khan
dA
ssam
Kera
la
Sikk
im
Aru
nach
al P
rade
sh
Jam
mu
& K
ashm
ir
Utt
arak
hand
Del
hi
Goa
Mah
aras
htra
Karn
atak
a
And
hra
Prad
esh
Him
acha
l Pra
desh
-80.
4
-70.
6
-72.
6
-70.
3
-72.
6
-70.
0
-71.8 -70.
0-6
7.4-6
5.2
-55.
9-5
3.4
-53.
2-5
2.4
-50.
6-5
0.0
-38.
7-3
7.7-3
4.7
-32.
7-2
6.4
-20.
5-1
8.2
-14.3
-14.2 -4
.7
80.0
20.0
2.91.80.3
0.0
135.
588
.9150
0
-150
Figure 20: Need for PMTCT of HIV by State/UT, 2019
Trip
ura
Man
ipur
Miz
oram
Meg
hala
ya
Pudu
cher
ry
Tela
ngan
a
Punj
ab
Tam
il N
adu
Nag
alan
dH
arya
na
Guj
arat
Odi
sha
Biha
r
Chh
attis
garh
Cha
ndig
arh
Raja
stha
n
Mad
hya
Prad
esh
And
aman
& N
icob
ar
Dad
ra &
Nag
ar
Dam
an &
Diu
Utt
ar P
rade
sh
Wes
t Ben
gal
Jhar
khan
dA
ssam
Kera
la
Sikk
im
Aru
nach
al P
rade
sh
Jam
mu
& K
ashm
irU
ttar
akha
nd
Del
hi
Goa
Mah
aras
htra
Karn
atak
aA
ndhr
a Pr
ades
h
Him
acha
l Pra
desh
3,0
072,
525
2,21
21,3
921,3
861,0
2998
586
484
567
960
658
057
448
546
442
339
735
934
632
727
826
5
96 53 50 34 21 12 12 8 4 4533155
5,000
4,000
3,000
2,000
1,000
0
INDIA HIV ESTIMATES 2019
23
05 Discussion
As a signatory to the United Nations declaration on Sustainable Development Goals (SDGs), India is committed to achieving the “End of AIDS” as a public health threat by 2030. Specific 2020 Fast-Track Targets, including 75% decline in new HIV infections from the 2010 baseline value, attainment of 90-90-90 treatment goals, elimination of mother-to-child transmission of HIV and elimination of HIV/AIDS-related stigma and discrimination, have been identified to anchor the global AIDS response towards attaining the “ENDGAME” by 2030. HIV Estimations 2019 provides critical epidemiological updates using the latest tool and data not only by informing the policymakers, programme managers and all other related stakeholders on the latest status of the epidemic but also as the present benchmark to inform the progress on 2020 Fast-Track Targets and 2030 “End of AIDS” goal.
HIV Estimations 2019 has reiterated that while India’s successful response to AIDS epidemic continues, there is no scope for complacency. While adult HIV prevalence has continued to decline nationally and
in many of the erstwhile high prevalence southern and western States, it has been rising in many States, probably reflecting the increasing survival of HIV-infected population due to successful care, support and treatment programme. Gradual increase in the number of PLHIV in various States/UTs in the coming years will have to be accounted for by the programme during the strategic planning of the activities such as HIV testing, ART treatment, etc.
In the erstwhile high prevalence and early epidemic States of Andhra Pradesh, Maharasthra, Karnataka, Tamil Nadu and Telangana, both the prevention and treatment programmes have been highly successful. As the annual new infections have declined more than annual deaths, the prevalence has declined in these States, which can be attributed to the significant impact of the national programme.
The results on new HIV infections suggest that while success on prevention aspects continue, the current achievement is still far from the target set. Nationally, new HIV infections have declined by 37% between
INDIA HIV ESTIMATES 2019
24
2010 and 2019 in comparison to the global average of 23% (between 2010 and 2019) but yet far from the envisaged target of 75%.
State/UT-wise, till 2019, Karnataka has already achieved the 2020 prevention targets, with Himachal Pradesh and Andhra Pradesh also nearing the targets. It is a concern that no other States/UTs have achieved a decline of 60% or more till 2019. Tripura, Arunachal Pradesh, Chhattisgarh, West Bengal, Mizoram and Nagaland face a major challenge of preventing new HIV infections, where it has continued to rise/remain stable between 2010 and 2019.
Care, support and treatment (CST) programme has been at the core of India’s successful AIDS response. Although its implementation followed that of prevention activities by almost two decades and they were initiated as late as in 2004, rapid scale-up of CST programme under NACP has set up a global benchmark. Between 2010 and 2019 in India, the number of PLHIV on ART has increased almost fourfold while globally, the same has increased threefold (between 2010 and 2018). During the period between 2010 and 2019, AIDS-related deaths have declined nationally by almost 66% in comparison to the global average of 39% decline against the target to achieve 75% decline by 2020. In the erstwhile high prevalence States of Andhra Pradesh, Karnataka, Maharasthra, Tamil Nadu and Telangana, the decline in AIDS-related deaths has ranged from 70% to 80% (between 2010 and 2019), which has been a major reason for the decline
seen at the national level. Meghalaya, Arunachal Pradesh, Tripura, Jammu and Kashmir, Jharkhand, Assam, Sikkim, Bihar and Delhi have exhibited a stable to rising trend in AIDS-related deaths. This is an area of concern and needs exploration and appropriate programmatic response.
The status of HIV/AIDS epidemic in the States of north-eastern India is indeed alarming. Except for Manipur, the HIV prevalence in these States has shown a stable to rising trend due to a relatively higher number of annual new HIV infections. Annual new HIV infections have, in fact, increased in Arunachal Pradesh and Tripura while being almost stable in Mizoram and Nagaland during 2010–2019. There is a clear need for community-driven integrated AIDS response in these States on an urgent basis to respond to the growing HIV problem in the region.
Under the NACP in India, HIV Estimations 2019 has established that the country is on track to achieve the reductions in AIDS-related deaths nationally as well as in many States/UTs. However, the initiatives for arresting the number of new HIV infections require more focused attention to achieve the SDG Target 3.3.1. Further insights on district-level estimates will provide a more granular understanding of the epidemic in the States/UTs of special concern because that data will be more meaningful in micro-planning, local-level prioritization and local programmatic response.
INDIA HIV ESTIMATES 2019
25
Annexures
INDIA HIV ESTIMATES 2019
26
Annexure 1: Composition of the National Working Group on HIV Estimations 2019
INDIA HIV ESTIMATES 2019
27
INDIA HIV ESTIMATES 2019
28
INDIA HIV ESTIMATES 2019
29
INDIA HIV ESTIMATES 2019
30
INDIA HIV ESTIMATES 2019
31
INDIA HIV ESTIMATES 2019
32
INDIA HIV ESTIMATES 2019
33
Annexure 2: Composition of Technical Resource Group on HIV Surveillance and Estimation
Chair: Shri Sanjeeva Kumar, Former Special Secretary and Director General, NACO /Smt Arti Ahuja, Additional Secretary and Director General, NACO
Co-chair: Dr. Sanjay Mehendale, Additional Director General, ICMR
Member Secretary: Dr. Shobini Rajan, DDG (Surveillance & Epidemiology), NACO
Members:
1. Shri Alok Saxena, Joint Secretary, NACO
2. Dr. Henk Bekedam, Country Representative, WHO India
3. Dr. Bilali Camara, Country Director, UNAIDS India
4. Dr. N. S. Dharmshaktu, Principal Advisor to Ministry on Public Health, MoHFW, GOI
5. Dr. Peter Ghys, Director, Strategic Information and Evaluation, UNAIDS, Geneva
6. Dr. D. C. S. Reddy, Former Head of Department, Department of Community Medicine, Banaras Hindu University, Lucknow and Ex-NPO, WHO India
7. Prof. Arvind Pandey, Advisor, National Institute of Medical Statistics, New Delhi
8. Dr. Rajesh Kumar, Head, School of Public Health, PGIMER, Chandigarh
9. Dr. Samiran Panda, Director, National AIDS Research Institute, Pune
10. Dr. Manoj Vasant Murhekar, Director, National Institute of Epidemiology, Chennai
11. Dr. Shanta Dutta, Director, National Institute of Cholera and Enteric Diseases, Kolkata
12. Dr. Shashi Kant, Professor and Head, Centre for Community Medicine, All India Institute for Medical Sciences, New Delhi
13. Dr. S. Baby Vasumathi, Director, Institute of Obstetrics & Gynaecology, Madras Medical College, Chennai
14. Dr. Sanjay Dixit, Department of Community Medicine, MGM Medical College, Indore
INDIA HIV ESTIMATES 2019
34
15. Dr. D. K. Shukla, Former I/C Director, ICMR-NIMS, New Delhi
16. Dr. Laxmisha Chandrashekar, Head of Department, Department of Dermatology and STD, JIPMER, Puducherry
17. Mr. Taoufik Bakkali, UNAIDS Regional Support Team for Asia and the Pacific, Bangkok
18. Dr. Laishram Ladu Singh, Off iciating Director, International Institute for Population Sciences, Mumbai
19. Dr. Jagdish Chandra, Former Director, Kalawati Saran Children’s Hospital, New Delhi
20. Dr. Timothy Holtz, Director, DGHT, CDC India
21. Dr. John Stover, Vice President, Avenir Health and member UNAIDS HIV Estimation Reference Group
22. Mr. Ashok R. Kavi, Chairman, The Humsafar Trust
23. Mx. Abhina Aher, Associate Director, India HIV/AIDS Alliance
24. Dr. Naresh Goel, Deputy Director General, NACO
25. Dr. R. S. Gupta, Former Deputy Director General, NACO
26. Dr. Anoop Kumar Puri, Deputy Director General, NACO
Overall Coordination
1. Dr. Damodar Sahu, Scientist F & HIV Estimation Focal Person, ICMR-NIMS
2. Dr. Pradeep Kumar, Programme Off icer, Surveillance, NACO
INDIA HIV ESTIMATES 2019
35
Anne
xure
3: S
tate
and
Uni
on T
errit
ory-
wis
e Su
mm
ary
of H
IV E
pide
mic
in 2
019,
Indi
a H
IV E
stim
ates
201
9
No.
Stat
e/UT
Perc
enta
ge of
adult
HIV
pr
evale
nce (
15–4
9 yrs)
, 20
19To
tal n
umbe
r of P
LHIV,
2019
(in
thou
sand
)HI
V inc
iden
ce pe
r 1,0
00
uninf
ecte
d pop
ulatio
n, 20
19To
tal n
umbe
r of a
nnua
l new
HI
V inf
ectio
ns, 2
019
(in th
ousa
nd)
% ch
ange
in
annu
al ne
w HI
V inf
ectio
ns,
2010
–20
19
AIDS
-relat
ed m
orta
lity p
er
100,0
00 po
pulat
ion, 2
019
Tota
l num
ber o
f ann
ual A
IDS-
relat
ed de
aths
, 201
9 (in
thou
sand
)
% ch
ange
in
annu
al AI
DS
relat
ed
deat
hs,
2010
–20
19
PMTC
T nee
ds (in
thou
sand
)
Lowe
r bo
und
Estim
ate
Uppe
r bo
und
Lowe
r bo
und
Estim
ate
Uppe
r bo
und
Lowe
r bo
und
Estim
ate
Uppe
r bo
und
Lowe
r bo
und
Estim
ate
Uppe
r bo
und
Lowe
r bo
und
Estim
ate
Uppe
r bo
und
Lowe
r bo
und
Estim
ate
Uppe
r bo
und
Lowe
r bo
und
Estim
ate
Uppe
r bo
und
1An
dam
an &
Ni
coba
r 0.0
50.1
40.
370.
200.4
91.2
90.0
10.0
50.
290.0
10.0
20.1
3-5
2.38
0.50
4.05
12.41
0.00
0.02
0.06
-14.29
0.00
0.01
0.01
2An
dhra
Prad
esh
0.54
0.69
0.89
247.1
331
3.73
404.4
60.0
20.0
50.1
31.0
62.8
26.6
9-6
4.87
12.32
21.76
34.43
6.48
11.43
18.10
-70.0
30.9
81.3
92.0
1
3Ar
unac
hal
Prad
esh
0.04
0.06
0.10.
390.6
61.0
30.0
20.0
50.0
90.0
30.0
70.1
462
.220.4
81.1
42.1
10.0
10.0
20.0
388
.890.0
10.0
10.0
1
4As
sam
0.0
80.0
90.1
18.97
21.22
24.42
0.03
0.04
0.05
1.01
1.33
1.78
-22.7
51.2
31.6
72.1
80.4
20.
570.7
51.7
90.
280.
330.4
05
Biha
r 0.1
10.1
80.
2483
.02
134.4
918
5.61
0.03
0.07
0.12
3.23
8.04
13.47
-26.9
10.7
02.0
43.8
20.7
92.3
34.3
5-0
.301.6
02.5
33.5
46
Chan
diga
rh0.1
20.1
90.
261.5
22.3
63.1
90.0
30.0
80.1
40.0
40.1
20.
206.3
12.7
75.7
48.8
80.0
40.0
90.1
3-3
8.73
0.01
0.01
0.02
7Ch
hatti
sgar
h 0.1
50.
20.
2731
.9942
.5255
.460.0
60.1
00.1
51.7
02.8
34.1
16.5
53.3
05.2
58.0
30.9
31.4
82.2
6-5
5.89
0.41
0.58
0.80
8Da
dra &
Nag
ar0.1
40.
230.
370.4
70.7
51.1
90.0
60.1
70.
320.0
30.0
70.1
472
.09
0.91
1.89
4.49
0.00
0.01
0.02
-18.18
0.01
0.01
0.02
9Da
man
& D
iu 0.1
20.1
70.
230.
340.4
70.6
70.0
30.0
70.1
30.0
10.0
20.0
44.5
51.0
61.6
73.0
20.0
00.0
10.0
1-70
.00
0.00
0.00
0.01
10De
lhi
0.33
0.41
0.5
55.64
67.94
83.49
0.10
0.15
0.22
1.95
2.99
4.55
-35.9
43.1
95.2
18.4
70.6
71.1
01.7
9-4
.670.4
60.
570.7
211
Goa
0.19
0.27
0.46
3.20
4.53
7.53
0.01
0.03
0.14
0.01
0.06
0.24
-44.0
04.9
59.6
826
.140.0
90.1
70.4
6-6
5.24
0.02
0.02
0.04
12Gu
jarat
0.1
70.
20.
2293
.2710
3.51
119.49
0.04
0.05
0.07
2.62
3.37
4.52
-35.1
71.8
32.3
73.1
91.2
11.5
72.1
2-5
0.55
0.85
0.99
1.20
13Ha
ryan
a 0.1
70.
210.
2637
.2544
.7655
.160.0
60.0
90.1
31.7
22.6
23.6
6-12
.355.2
46.8
38.9
71.4
91.9
52.5
6-2
6.37
0.33
0.42
0.54
14Hi
mac
hal P
rade
sh
0.09
0.12
0.15
5.60
7.05
8.80
0.02
0.02
0.03
0.11
0.16
0.24
-73.75
0.62
0.96
1.77
0.05
0.07
0.13
-70.59
0.04
0.05
0.07
15Ja
mm
u &
Kash
mir
and
Lada
kh
0.03
0.06
0.11
3.16
6.04
10.47
0.01
0.02
0.07
0.10
0.32
0.92
-35.9
80.
230.9
72.2
80.0
30.1
30.
3120
.00
0.03
0.05
0.09
16Jh
arkh
and
0.06
0.09
0.13
14.92
22.75
33.65
0.02
0.04
0.07
0.60
1.30
2.41
-24.81
0.37
1.17
2.49
0.13
0.43
0.91
2.90
0.23
0.35
0.53
17Ka
rnat
aka
0.37
0.47
0.59
218.7
126
9.47
338.7
10.0
10.0
20.0
50.7
01.5
73.5
3-75
.155.8
89.7
216
.283.8
66.3
910
.69-8
0.36
1.00
1.39
2.00
18Ke
rala
0.07
0.08
0.11
20.18
24.21
31.83
0.01
0.02
0.05
0.50
0.80
1.59
-24.20
1.00
1.50
2.82
0.35
0.53
0.99
-53.3
70.1
20.1
60.
2419
Mad
hya P
rade
sh
0.08
0.10.1
446
.3459
.3080
.100.0
20.0
40.0
61.6
02.8
94.7
7-16
.241.4
02.2
33.6
31.1
41.8
22.9
6-5
3.16
0.43
0.61
0.86
20M
ahar
asht
ra
0.25
0.36
0.53
288.6
039
6.35
577.0
10.0
30.0
70.1
63.7
78.5
420
.10-3
8.38
3.96
7.81
16.96
4.91
9.69
21.0
5-71
.812.2
73.0
14.1
221
Man
ipur
0.9
71.1
81.4
623
.5528
.5635
.190.1
70.
340.
590.4
80.9
61.6
9-2
9.09
24.59
36.86
56.70
0.72
1.08
1.66
-52.4
20.
260.
360.
5022
Meg
halay
a 0.4
60.
540.6
39.5
111.
2813
.08
0.18
0.23
0.31
0.57
0.73
0.98
-48.6
78.1
711.
0813
.890.
260.
360.4
513
5.53
0.23
0.28
0.34
23M
izora
m1.8
52.3
22.8
416
.1220
.05
24.62
0.73
1.18
1.70
0.85
1.37
1.96
-0.51
17.49
28.34
43.93
0.21
0.34
0.52
-50.0
00.
210.
270.
3324
Naga
land
1.15
1.45
1.78
18.0
522
.5527
.410.4
90.7
30.9
71.0
41.5
52.0
5-6
.4715
.3426
.2038
.700.
330.
570.
84-3
4.72
0.31
0.40
0.50
25Od
isha
0.12
0.14
0.17
42.81
49.15
59.22
0.04
0.05
0.07
1.62
2.17
2.97
-38.3
32.8
53.8
85.4
21.2
81.7
42.4
3-3
2.73
0.40
0.49
0.61
26Pu
duch
erry
0.
20.
350.
582.8
34.7
77.8
40.0
60.1
60.
380.1
00.
260.6
1-3
9.06
6.18
15.33
29.63
0.11
0.26
0.50
364.2
90.0
20.0
30.0
627
Punja
b 0.
220.
270.
3554
.1865
.8384
.510.0
50.0
80.1
41.4
02.3
74.1
0-3
6.60
3.25
4.75
7.79
0.97
1.42
2.33
-67.4
40.
360.4
60.6
328
Rajas
than
0.0
80.1
10.1
447
.5962
.9876
.400.0
20.0
40.0
51.5
82.7
73.9
8-4
1.59
0.46
0.93
1.57
0.36
0.71
1.20
-20.4
90.6
40.
861.0
629
Sikk
im
0.03
0.07
0.15
0.19
0.35
0.76
0.01
0.03
0.12
0.01
0.02
0.08
-34.3
80.1
70.6
42.3
50.0
00.0
00.0
20.0
00.0
00.0
00.0
130
Tam
il Nad
u 0.1
60.
230.
29114
.3715
4.61
197.8
40.0
10.0
40.0
71.0
82.6
24.9
0-4
4.38
2.22
4.01
7.09
1.67
3.01
5.33
-72.62
0.56
0.85
1.20
31Te
langa
na
0.35
0.49
0.66
114.95
157.5
121
3.21
0.03
0.08
0.16
1.06
2.82
5.95
-52.0
66.0
310
.7918
.06
2.28
4.08
6.84
-72.64
0.68
1.03
1.52
32Tr
ipur
a0.0
70.1
0.13
2.04
2.86
3.77
0.07
0.11
0.17
0.29
0.45
0.65
264.5
20.
200.4
60.9
10.0
10.0
20.0
480
.00
0.02
0.03
0.04
33Ut
tara
khan
d0.1
0.13
0.17
8.49
10.96
14.19
0.03
0.04
0.07
0.31
0.49
0.77
-46.0
91.8
43.0
84.8
10.
210.
340.
54-14
.210.0
70.1
00.1
334
Utta
r Pra
desh
0.0
70.1
0.13
120.7
816
0.60
213.6
30.0
20.0
30.0
53.9
36.7
210
.60-4
6.37
0.84
1.71
3.03
1.91
3.87
6.89
-37.7
01.7
22.2
12.9
435
Wes
t Ben
gal
0.07
0.09
0.13
52.65
74.20
103.6
10.0
20.0
40.0
71.9
43.9
76.9
80.
510.7
01.4
02.9
80.6
81.3
72.9
2-70
.340.4
50.6
81.0
5IN
DIA
0.17
0.22
0.29
1,798
.992,3
48.86
3,098
.830.0
30.0
50.0
937
.03
69.22
121.5
1-3
7.38
2.51
4.43
7.59
33.61
58.9
610
2.17
-66.0
714
.9820
.5228
.13
INDIA HIV ESTIMATES 2019
36
INDIA HIV ESTIMATES 2019
37
Factsheets
And
aman
and
Nic
obar
Isla
nds
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
16Fe
mal
e0.
12
Mal
e0.
05
Fe
mal
e0.
04
0.
47Ad
ults
(15+
yea
rs)
0.19
Fe
mal
e(1
5+ y
ears
)
0.0
1 C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.0
1 Ad
ults
(15+
yea
rs)
0.0
06
Fem
ale
(15+
yea
rs)
0.0
01
Chi
ldre
n(<
15 y
ears
)
52.3
8 To
tal
52.5
Ad
ults
(15+
yea
rs)
53.3
Fe
mal
e(1
5+ y
ears
)
33.3
C
hild
ren
(<15
yea
rs)
0.0
19
Adul
ts(1
5+ y
ears
)
0.0
07
Fem
ale
(15+
yea
rs)
0.0
02
Chi
ldre
n(<
15 y
ears
)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
14.2
9 To
tal
15.0
Adul
ts (1
5+ y
ears
)
14.3
Fem
ale
(15+
yea
rs)
50.0
Chi
ldre
n (<
15 y
ears
)
0.0
1 [0
.00
-0.0
1]
0.0
2To
tal
[0.0
02
-0.0
6]
[0.0
02-
0.0
5][0
.00
-0.0
1][0
.00
-0.0
04]
0.0
2 To
tal
[0.0
1 -0.
13]
[0.0
06-0
.121]
[0.0
02-0
.05]
[0.0
01-0
.006
]
[0.0
1-0.
24]
[0.0
2-0.
33]
0.0
5To
tal
[0.0
1-0.
29]
0.14
Tota
l[0
.05-
0.37
]
[0.0
6-0.
43]
[0.0
5-0.
31]
0.49
Tot
al
[0.2
0 -1
.29]
[0.19
-1.2
5][0
.07-
0.51
][0
.007
-0.0
4]
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.01.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
0.3
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
25.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
38
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
39
And
hra
Prad
esh
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
74Fe
mal
e0.
64M
ale
0.0
6Fe
mal
e0.
05
306.
53Ad
ults
(15+
yea
rs)
143.
66
Fem
ale
(15+
yea
rs)
7.19
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
11.19
Adul
ts(1
5+ y
ears
)
3.15
Fe
mal
e(1
5+ y
ears
)
0.24
C
hild
ren
(<15
yea
rs)
64.8
7 To
tal
60.6
Adul
ts(1
5+ y
ears
)
60.7
Fe
mal
e(1
5+ y
ears
)
87.8
C
hild
ren
(<15
yea
rs)
2.66
Adul
ts(1
5+ y
ears
)
1.15
Fem
ale
(15+
yea
rs)
0.15
C
hild
ren
(<15
yea
rs)
1.39
[0.9
8-2.
01]
11.4
3To
tal
[6.4
8-18
.10]
[6.2
9- 1
7.82
][1
.57-
5.5
7][0
.12- 0
.40
]
2.82
Tota
l [1
.06-
6.6
9]
[0.9
6- 6
.43]
[0.4
2- 2
.73]
[0.0
8-0.
26]
[0.0
2-0.
11]
[0.0
2-0.
15]
0.0
5To
tal
[0.0
2- 0
.13]
0.69
Tota
l[0
.54-
0.89
]
[0.5
5-0.
98]
[0.5
1-0.
82]
313.
73 T
otal
[2
47.13
- 40
4.46
]
[241
.05-
395
.46]
[ 114
.86-
182.
88]
[5.2
6-9.
39]
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.3
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
100.
0A
IDS
mor
talit
y pe
r 10
0,0
00
pop
ulat
ion
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.07.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
70.0
3 To
tal
69.3
Adul
ts (1
5+ y
ears
)
78.3
Fem
ale
(15+
yea
rs)
85.5
Chi
ldre
n (<
15 y
ears
)
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
07
Fem
ale
0.0
5M
ale
0.0
6 Fe
mal
e0.
04
0.63
Adul
ts(1
5+ y
ears
)
0.25
Fe
mal
e(1
5+ y
ears
)
0.0
2 C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Incr
ease
/Dec
line
in n
ew
HIV
infe
ctio
ns s
ince
20
10
(%)
AID
S-re
late
d m
orta
lity
(in th
ousa
nd)
0.0
15
Adul
ts(1
5+ y
ears
)
0.0
05
Fem
ale
(15+
yea
rs)
0.0
02
Chi
ldre
n(<
15 y
ears
)
62.2
2+
Tota
l
69.0
+ Ad
ults
(15+
yea
rs)
75.0
+ Fe
mal
e(1
5+ y
ears
)
33.3
- C
hild
ren
(<15
yea
rs)
0.0
7 Ad
ults
(15+
yea
rs)
0.0
2 Fe
mal
e(1
5+ y
ears
)
0.0
02
Chi
ldre
n(<
15 y
ears
)
Incr
ease
/Sta
bilit
y in
AID
S-re
late
d m
orta
lity
sinc
e 20
10 (%
)
88.8
9+
Tota
l
114.
3+Ad
ults
(15+
yea
rs)
66.7
+Fe
mal
e (1
5+ y
ears
)
0.0
Chi
ldre
n (<
15 y
ears
)
0.0
1[0
.01-
0.0
1]
0.0
2To
tal
[0.0
1-0.
03]
[0.0
06-
0.0
28]
[0.0
02-
0.0
10]
[0.0
01-
0.0
04]
0.0
7To
tal
[0.0
3-0.
14]
[0.0
2-0.
13]
[0.0
1-0.
05]
[0.0
01-
0.0
03]
[0.0
2-0.
08]
[0.0
2-0.
11]
0.0
5To
tal
[0.0
2-0.
09]
0.0
6To
tal
[0.0
4-0.
10]
[0.0
4-0.
12]
[0.0
3-0.
09]
0.66
Tot
al
[0.3
9-1.
03]
[0.3
6-0.
99]
[0.14
-0.3
9][0
.01-
0.0
3]
Aru
nach
al P
rade
sh
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.05.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
0.3
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
0.3
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
40
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
41
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
09
Fem
ale
0.0
8 M
ale
0.0
4 Fe
mal
e0.
04
20.2
8Ad
ults
(15+
yea
rs)
8.93
Fe
mal
e(1
5+ y
ears
)
0.93
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.50
Ad
ults
(15+
yea
rs)
0.20
Fe
mal
e(1
5+ y
ears
)
0.0
6 C
hild
ren
(<15
yea
rs)
22.7
5 To
tal
19.7
Ad
ults
(15+
yea
rs)
13.2
Fe
mal
e(1
5+ y
ears
)
55.6
C
hild
ren
(<15
yea
rs)
1.26
Ad
ults
(15+
yea
rs)
0.59
Fe
mal
e(1
5+ y
ears
)
0.0
6 C
hild
ren
(<15
yea
rs)
Incr
ease
/Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
1.79+
To
tal
5.5+
Adul
ts (1
5+ y
ears
)
6.1+
Fem
ale
(15+
yea
rs)
19.0
-C
hild
ren
(<15
yea
rs)
0.33
[0.2
8-0.
40]
0.57
To
tal
[0.4
2-0.
75]
[0.3
6-0.
66]
[0.14
-0.2
8][0
.05-
0.08
]
1.33
To
tal
[1.0
1-1.7
8]
[0.9
6-1.7
0]
[0.4
5-0.
82]
[0.0
5-0.
08]
[0.0
3-0.
05]
[0.0
3-0.
06]
0.0
4 To
tal
[0.0
3-0.
05]
0.0
9To
tal
[0.0
8-0.
10]
[0.0
8-0.
11]
[0.0
7-0.
09]
21.2
2 To
tal
[18.
97-2
4.42
]
[18.
09-
23.3
6][7
.88-
10.3
3][0
.81-
1.08]
Ass
am
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
5.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
0.3
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.3
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
20
Fem
ale
0.15
M
ale
0.0
8Fe
mal
e0.
06
127.
16Ad
ults
(15+
yea
rs)
52.3
8 Fe
mal
e(1
5+ y
ears
)
7.31
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
1.78
Ad
ults
(15+
yea
rs)
0.51
Fe
mal
e(1
5+ y
ears
)
0.54
C
hild
ren
(<15
yea
rs)
26.9
1 To
tal
27.5
Ad
ults
(15+
yea
rs)
26.9
Fe
mal
e(1
5+ y
ears
)
20.1
Chi
ldre
n(<
15 y
ears
)
7.33
Ad
ults
(15+
yea
rs)
2.97
Fe
mal
e(1
5+ y
ears
)
0.70
C
hild
ren
(<15
yea
rs)
Incr
ease
/Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
0.30
- To
tal
0.28
+Ad
ults
(15+
yea
rs)
36.4
-Fe
mal
e (1
5+ y
ears
)
2.4-
Chi
ldre
n (<
15 y
ears
)
2.53
[1.6
0-3
.54]
2.33
Tota
l[0
.79-
4.35
]
[0.5
8-3.
43]
[0.13
-1.10
][0
.23-
0.86
]
8.0
4To
tal
[3.2
3-13
.47]
[2.8
6-12
.42]
[1.11
-5.10
][0
.36-
1.06]
[0.0
2-0.
10]
[0.0
3-0.
14]
0.0
7To
tal
[0.0
3-0.
12]
0.18
Tota
l[0
.11-0
.24]
[0.12
-0.2
8][0
.09-
0.21
]
134.
49 T
otal
[8
3.0
2-18
5.61
]
[78.
17-1
75.3
6][3
1.69-
72.4
4][4
.56-
10.19
]
Biha
r
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.3
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
5.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.00.7
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
42
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
43
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
22
Fem
ale
0.14
Mal
e0.
10
Fem
ale
0.0
5 2.
29Ad
ults
(15+
yea
rs)
0.67
Fe
mal
e(1
5+ y
ears
)
0.0
6 C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Incr
ease
/Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.0
8 Ad
ults
(15+
yea
rs)
0.0
1 Fe
mal
e(1
5+ y
ears
)
0.0
03
Chi
ldre
n(<
15 y
ears
)
6.31
+ To
tal
9.5+
Ad
ults
(15+
yea
rs)
3.1-
Fe
mal
e(1
5+ y
ears
)
71.4
- C
hild
ren
(<15
yea
rs)
0.11
Ad
ults
(15+
yea
rs)
0.0
3 Fe
mal
e(1
5+ y
ears
)
0.0
02
Chi
ldre
n(<
15 y
ears
)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
38.7
3 To
tal
38.7
Adul
ts (1
5+ y
ears
)
61.0
Fem
ale
(15+
yea
rs)
25.0
Chi
ldre
n (<
15 y
ears
)
0.0
1 [0
.01-
0.0
2 ]
0.0
9To
tal
[0.0
4-0.
13]
[0.0
4-0.
13]
[0.0
07-0
.02]
[0.0
01-
0.0
04]
0.12
To
tal
[0.0
4-0.
20]
[0.0
3-0.
19]
[0.0
1-0.
05]
[0.0
01-0
.003
]
[0.0
2-0.
09]
[0.0
3-0.
17]
0.0
8To
tal
[0.0
3-0.
14]
0.19
To
tal
[0.12
-0.2
6]
[0.14
-0.3
1]
2.36
Tot
al
[1.5
2-3.
19]
[1.4
7-3.
10]
[0.4
5-0.
88]
[0.0
4-0.
07]
Cha
ndig
arh
[0.0
9-0.
19]
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.3
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
25.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
2.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
22
Fem
ale
0.19
M
ale
0.10
Fem
ale
0.10
40.4
1Ad
ults
(15+
yea
rs)
18.7
7 Fe
mal
e(1
5+ y
ears
)
2.11
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Incr
ease
/Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
1.33
Ad
ults
(15+
yea
rs)
0.55
Fe
mal
e(1
5+ y
ears
)
0.14
C
hild
ren
(<15
yea
rs)
6.55
+ To
tal
10.5
+ Ad
ults
(15+
yea
rs)
17.5
+ Fe
mal
e(1
5+ y
ears
)
25.3
- C
hild
ren
(<15
yea
rs)
2.61
Ad
ults
(15+
yea
rs)
1.30
Fe
mal
e(1
5+ y
ears
)
0.21
C
hild
ren
(<15
yea
rs)
0.58
[0.4
1-0.
80]
1.48
Tota
l[0
.93-
2.26
]
[0.8
2-2.
05]
[0.3
3-0.
86]
[0.0
9-0.
21]
2.83
Tota
l [1
.70
-4.11
]
[1.5
4-3.
81]
[0.7
6-1.9
3][0
.14-0
.30
]
[0.0
6-0.
15]
[0.0
6-0.
15]
0.10
Tota
l [0
.06-
0.15
]
0.20
Tota
l[0
.15-0
.27]
[0.16
-0.2
8][0
.14-0
.25]
42.5
2 To
tal
[31.
99-5
5.46
]
[30.
36-5
2.70
][1
4.0
9-25
.06]
[1.6
2-2.
80]
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
55.8
9 To
tal
57.0
Adul
ts (1
5+ y
ears
)
58.0
Fem
ale
(15+
yea
rs)
42.0
Chi
ldre
n (<
15 y
ears
)
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.3
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
25.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
2.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
Chh
attis
garh
44
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
45
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
17Fe
mal
e0.
14
Mal
e0.
08
Fem
ale
0.0
5 0.
45Ad
ults
(15+
yea
rs)
0.11
Fe
mal
e(1
5+ y
ears
)
0.0
1 C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Incr
ease
/Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.0
05
Adul
ts(1
5+ y
ears
)
0.0
01
Fem
ale
(15+
yea
rs)
0.0
01
Chi
ldre
n(<
15 y
ears
)
4.55
+ To
tal
10.0
+ Ad
ults
(15+
yea
rs)
16.7
- Fe
mal
e(1
5+ y
ears
)
50.0
- C
hild
ren
(<15
yea
rs)
0.0
2 Ad
ults
(15+
yea
rs)
0.0
05
Fem
ale
(15+
yea
rs)
0.0
01
Chi
ldre
n(<
15 y
ears
)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
70.0
To
tal
72.2
Adul
ts (1
5+ y
ears
)
83.3
Fem
ale
(15+
yea
rs)
0.0
Chi
ldre
n (<
15 y
ears
)
0.0
04
[0.0
03-
0.0
06]
0.0
1 To
tal
[0.0
0-0
.01 ]
[0.0
03-
0.0
09]
[0.0
01-0
.003
][0
.00
1-0.
00
1]
0.0
2To
tal
[0.0
1-0.
04]
[0.0
1-0.0
3][0
.003
-0.0
09]
[0.0
01-0
.002
]
[0.0
3-0.
10]
[0.0
4-0.
14]
0.
07
To
ta
l [0
.03-
0.13
]
0.17
To
tal
[0.12
-0.2
3]
[0.12
-0.2
5][0
.10-0
.20
]
0.47
Tot
al
[0.3
4-0.
67]
[0.3
2-1.1
5][0
.08-
0.16
][0
.007
-0.0
1]
Dam
an a
nd D
iu
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.5
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
15.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.01.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
26
Fem
ale
0.19
Mal
e0.
19
Fem
ale
0.14
0.
72Ad
ults
(15+
yea
rs)
0.26
Fe
mal
e(1
5+ y
ears
)
0.0
2 C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Incr
ease
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.0
06
Adul
ts(1
5+ y
ears
)
0.0
02
Fem
ale
(15+
yea
rs)
0.0
03
Chi
ldre
n(<
15 y
ears
)
72.0
9+
Tota
l
70.7
+ Ad
ults
(15+
yea
rs)
78.6
+Fe
mal
e(1
5+ y
ears
)
100
+ C
hild
ren
(<15
yea
rs)
0.0
7 Ad
ults
(15+
yea
rs)
0.0
2
Fem
ale
(15+
yea
rs)
0.0
04
Chi
ldre
n(<
15 y
ears
)
Incr
ease
/Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
18.8
- To
tal
40.0
-Ad
ults
(15+
yea
rs)
33.3
-Fe
mal
e (1
5+ y
ears
)
200
+C
hild
ren
(<15
yea
rs)
0.0
1 [0
.00
7-0.
018
]
0.0
1To
tal
[0.0
04-
0.0
2]
[0.0
02-
0.0
1][0
.001
-0.0
05]
[0.0
02-
0.0
05]
0.0
7To
tal
[0.0
3-0.
14]
[0.0
2-0.
13]
[0.0
09-0
.04]
[0.0
02-0
.007
]
[0.0
5-0.
26]
[0.0
7-0.
37]
0.17
To
tal
[0.0
6-0.
32]
0.23
To
tal
[0.14
-0.3
7]
[0.16
-0.4
1]
0.75
Tot
al
[0.4
7-1.1
9]
[0.4
5-1.1
5][0
.16-0
.41]
[0.0
1-0.
03]
Dad
ra a
nd N
agar
Hav
eli
[0.12
-0.3
0]
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
15.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.01.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.5
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
46
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
47
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
15.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.5
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
1.5A
dult
(15–
49 y
ears
) HIV
pre
vale
nce
0.0
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
47
Fem
ale
0.33
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
0.41
Tota
l[0
.33-
0.50
]
[0.3
8-0.
58]
[0.2
7-0.
41]
65.9
1Ad
ults
(15+
yea
rs)
23.8
4 Fe
mal
e(1
5+ y
ears
)
2.0
2
C
hild
ren
(<15
yea
rs)
67.9
4 To
tal
[55.
64-8
3.49
]
[53.
94-8
1.15]
[19.
35-2
9.0
0]
[1.6
8-2.
46]
Mal
e0.
16Fe
mal
e0.
12[0
.08-
0.19
][0
.11-0
.25]
0.15
Tota
l [0
.10-0
.22]
2.90
Ad
ults
(15+
yea
rs)
1.10
Fe
mal
e(1
5+ y
ears
)
0.0
8 C
hild
ren
(<15
yea
rs)
2.99
To
tal
[1.9
5-4.
55]
[1.8
9-4.
45]
[0.7
06-
1.69]
[0.0
5-0.
11]
35.9
4 To
tal
34.7
Ad
ults
(15+
yea
rs)
32.0
Fe
mal
e(1
5+ y
ears
)
62.0
C
hild
ren
(<15
yea
rs)
1.0
0
Adul
ts(1
5+ y
ears
)
0.29
Fe
mal
e(1
5+ y
ears
)
0.0
9 C
hild
ren
(<15
yea
rs)
1.10
Tota
l[0
.67-
1.79]
[0.6
1-1.6
5][0
.15-0
.52]
[0.0
6-0.
13]
4.67
To
tal
3.7
Adul
ts (1
5+ y
ears
)
14.8
Fem
ale
(15+
yea
rs)
12.6
Chi
ldre
n (<
15 y
ears
)
0.57
[0
.46-
0.72
]
Del
hi
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
29
Fem
ale
0.25
Mal
e0.
03
Fem
ale
0.0
34.
42Ad
ults
(15+
yea
rs)
1.83
Fe
mal
e(1
5+ y
ears
)
0.10
Chi
ldre
n(<
15 y
ears
)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.16
Ad
ults
(15+
yea
rs)
0.0
3 Fe
mal
e(1
5+ y
ears
)
0.0
02
Chi
ldre
n(<
15 y
ears
)
44.0
0
Tota
l
40.2
Ad
ults
(15+
yea
rs)
41.0
Fe
mal
e(1
5+ y
ears
)
69.2
C
hild
ren
(<15
yea
rs)
0.0
5
Adul
ts(1
5+ y
ears
)
0.0
2
Fem
ale
(15+
yea
rs)
0.0
04
Chi
ldre
n(<
15 y
ears
)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
65.2
4 To
tal
64.6
Adul
ts (1
5+ y
ears
)
81.8
Fem
ale
(15+
yea
rs)
86.7
Chi
ldre
n (<
15 y
ears
)
0.0
2[0
.02-
0.0
4]
0.17
Tota
l[0
.09-
0.46
]
[0.0
8-0.
44]
[0.0
1-0.
10]
[0.0
01-
0.0
09]
0.0
6To
tal
[0.0
1-0.
24]
[0.0
1-0.
22]
[0.0
05-
0.0
9][0
.00
2-0.
01]
[0.0
1-0.
13]
[0.0
1-0.
14]
0.0
3To
tal
[0.0
1-0.
14]
0.27
To
tal
[0.19
-0.4
6]
[0.2
0-0
.48]
[0.18
-0.4
3]
4.53
Tot
al
[3.2
0-7
.53]
[3.13
-7.3
1][1
.27-
3.0
3][0
.06-
0.20
]
Goa
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
50.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
6.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.2
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
48
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
49
Guj
arat
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.3
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
10.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.01.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
Mal
e0.
05
Fem
ale
0.0
5[0
.04-
0.07
][0
.04-
0.07
]
0.0
5To
tal
[0.0
4-0.
07]
99.7
1Ad
ults
(15+
yea
rs)
42.2
6 Fe
mal
e(1
5+ y
ears
)
3.79
Chi
ldre
n(<
15 y
ears
)
103.
51 T
otal
[9
3.27
-119
.49]
[89.
73-1
15.3
4][3
7.86
-48.
04]
[3.3
5-4.
36]
3.22
Ad
ults
(15+
yea
rs)
1.48
Fe
mal
e(1
5+ y
ears
)
0.14
C
hild
ren
(<15
yea
rs)
3.37
To
tal
[2.6
2-4.
52]
[2.4
9-4.
34]
[1.13
-2.0
0]
[0.11
-0.17
]
35.17
To
tal
29.5
Ad
ults
(15+
yea
rs)
27.2
Fe
mal
e(1
5+ y
ears
)
77.1
Chi
ldre
n(<
15 y
ears
)
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
21Fe
mal
e0.
16
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
0.20
Tota
l[0
.17-0
.22]
[0.19
-0.2
5][0
.27-
0.41
]
50.5
5 To
tal
49.3
Adul
ts (1
5+ y
ears
)
56.3
Fem
ale
(15+
yea
rs)
59.8
Chi
ldre
n (<
15 y
ears
)
1.41
Ad
ults
(15+
yea
rs)
0.55
Fe
mal
e(1
5+ y
ears
)
0.15
C
hild
ren
(<15
yea
rs)
1.57
To
tal
[1.2
1-2.
12]
[1.0
8-1.9
3][0
.38-
0.78
][0
.12-0
.19]
0.99
[0.8
5-1.
20]
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
[0.13
-0.19
]
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
26
Fem
ale
0.15
M
ale
0.12
Fe
mal
e0.
07
43.2
6Ad
ults
(15+
yea
rs)
14.9
7 Fe
mal
e(1
5+ y
ears
)
1.49
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
1.84
Ad
ults
(15+
yea
rs)
0.49
Fe
mal
e(1
5+ y
ears
)
0.10
C
hild
ren
(<15
yea
rs)
12.3
5 To
tal
6.5
Adul
ts(1
5+ y
ears
)
8.2
Fem
ale
(15+
yea
rs)
71.7
C
hild
ren
(<15
yea
rs)
2.54
Ad
ults
(15+
yea
rs)
0.82
Fe
mal
e(1
5+ y
ears
)
0.0
7 C
hild
ren
(<15
yea
rs)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
26.3
7 To
tal
25.1
Adul
ts (1
5+ y
ears
)
36.0
Fem
ale
(15+
yea
rs)
43.4
Chi
ldre
n (<
15 y
ears
)
0.42
[0
.33-
0.54
]
1.95
Tota
l[1
.49-
2.56
]
[1.4
0-2
.42]
[0.3
6-0.
67]
[0.0
8-0.
13]
2.62
To
tal
[1.7
2-3.
66]
[1.6
6-3.
56]
[0.5
5-1.1
4][0
.05-
0.10
]
[0.0
4-0.
09]
[0.0
8-0.
16]
0.0
9To
tal
[0.0
6-0.
13]
0.21
To
tal
[0.17
-0.2
6]
[0.2
1-0.
32]
44.7
6 To
tal
[37.
25-5
5.16
]
[35.
91-5
3.44
][1
2.56
-18.
05]
[1.2
7-1.8
0]
Har
yana
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.3
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
15.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.01.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
50
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
51
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
14
Fem
ale
0.0
9M
ale
0.0
2Fe
mal
e0.
02
6.84
Adul
ts(1
5+ y
ears
)
2.61
Fe
mal
e(1
5+ y
ears
)
0.20
Chi
ldre
n(<
15 y
ears
)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.0
6
Adul
ts(1
5+ y
ears
)
0.0
1 Fe
mal
e(1
5+ y
ears
)
0.0
03
Chi
ldre
n(<
15 y
ears
)
73.7
5 To
tal
73.4
Ad
ults
(15+
yea
rs)
69.5
Fe
mal
e(1
5+ y
ears
)
81.5
C
hild
ren
(<15
yea
rs)
0.15
Ad
ults
(15+
yea
rs)
0.0
6
Fem
ale
(15+
yea
rs)
0.0
05
Chi
ldre
n(<
15 y
ears
)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
70.5
9 To
tal
69.2
Adul
ts (1
5+ y
ears
)
69.6
Fem
ale
(15+
yea
rs)
81.3
Chi
ldre
n (<
15 y
ears
)
0.0
5 [0
.04-
0.0
7]
0.0
7To
tal
[0.0
5-0.
13]
[0.0
4-0.
12]
[0.0
07-0
.02]
[0.0
01-
0.0
06]
0.16
Tota
l [0
.11-0
.24]
[0.11
-0.2
3][0
.04-
0.10
][0
.004
-0.0
08]
[0.0
1-0.
03]
[0.0
2-0.
04]
0.0
2 To
tal
[0.0
2-0.
03]
0.12
To
tal
[0.0
9-0.
15]
[0.11
-0.18
][0
.07-
0.12
]
7.0
5 To
tal
[5.6
0-8
.80
]
[5.4
4-8.
53]
[2.0
8-3.
33]
[0.15
-0.2
6]
Him
acha
l Pra
desh
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
0.3
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
10.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.01.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
07
Fe
mal
e0.
05
Mal
e0.
03
Fem
ale
0.0
25.
83Ad
ults
(15+
yea
rs)
2.19
Fe
mal
e(1
5+ y
ears
)
0.20
Chi
ldre
n(<
15 y
ears
)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.11
Ad
ults
(15+
yea
rs)
0.0
2 Fe
mal
e(1
5+ y
ears
)
0.0
1 C
hild
ren
(<15
yea
rs)
35.9
8 To
tal
34.9
Ad
ults
(15+
yea
rs)
20.6
Fe
mal
e(1
5+ y
ears
)
63.6
C
hild
ren
(<15
yea
rs)
0.30
Ad
ults
(15+
yea
rs)
0.12
Fe
mal
e(1
5+ y
ears
)
0.0
08
Chi
ldre
n(<
15 y
ears
)
Incr
ease
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
20.0
+ To
tal
21.6
+Ad
ults
(15+
yea
rs)
21.1+
Fem
ale
(15+
yea
rs)
7.7+
Chi
ldre
n (<
15 y
ears
)
0.0
5 [0
.03-
0.0
9]
0.13
To
tal
[0.0
3-0.
31]
[0.0
2-0.
28]
[0.0
03-
0.0
6][0
.004
-0.0
2]
0.32
To
tal
[0.10
-0.9
2]
[0.0
9-0.
90]
[0.0
4-0.
36]
[0.0
03-
0.0
1]
[0.0
1-0.
06]
[0.0
1-0.
08]
0.0
2 To
tal
[0.0
1-0.
07]
0.0
6 To
tal
[0.0
3-0.
11]
[0.0
4-0.
13]
[0.0
2-0.
09]
6.0
4 To
tal
[3.16
-10.
47]
[3.0
4-10
.22]
[1.11
-3.8
7][0
.11-0
.32]
Jam
mu
and
Kash
mir
and
Lada
kh
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
5.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
0.5
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
00.1
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
52
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
53
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
09
Fem
ale
0.0
8 M
ale
0.0
4 Fe
mal
e0.
03
21.5
6 Ad
ults
(15+
yea
rs)
9.57
Fe
mal
e(1
5+ y
ears
)
1.18
Chi
ldre
n(<
15 y
ears
)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.36
Ad
ults
(15+
yea
rs)
0.11
Fe
mal
e(1
5+ y
ears
)
0.0
6 C
hild
ren
(<15
yea
rs)
24.8
1 To
tal
24.3
Adul
ts(1
5+ y
ears
)
18.8
Fe
mal
e(1
5+ y
ears
)
29.7
C
hild
ren
(<15
yea
rs)
1.18
Adul
ts(1
5+ y
ears
)
0.55
Fe
mal
e(1
5+ y
ears
)
0.11
C
hild
ren
(<15
yea
rs)
Incr
ease
/Dec
line
in A
IDS-
rela
ted
mor
talit
ysi
nce
2010
(%)
2.90
+ To
tal
12.1+
Adul
ts (1
5+ y
ears
)
17.7
-Fe
mal
e (1
5+ y
ears
)
30.8
-C
hild
ren
(<15
yea
rs)
0.35
[0
.23-
0.53
]
0.43
To
tal
[0.13
-0.9
1]
[0.11
-0.7
9][0
.03-
0.30
][0
.02-
0.12
]
1.30
To
tal
[0.6
0-2
.41]
[0.5
4-2.
23]
[0.2
5-1.0
6][0
.06-
0.18
]
[0.0
2-0.
06]
[0.0
2-0.
07]
0.0
4To
tal
[0.0
2-0.
07]
0.0
9
Tota
l[0
.06-
0.13
]
[0.0
6-0.
14]
22.7
5 To
tal
[14.
92-3
3.65
]
[14.
13-3
1.82]
[6.17
-14.
28]
[0.7
6-1.7
5]
Jhar
khan
d
[0.0
5-0.
12]
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
00.1
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
5.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
0.5
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
45
Fem
ale
0.48
Mal
e0.
02
Fem
ale
0.0
226
1.15
Adul
ts(1
5+ y
ears
)
133.
21
Fem
ale
(15+
yea
rs)
8.31
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
6.13
Ad
ults
(15+
yea
rs)
2.0
5 Fe
mal
e(1
5+ y
ears
)
0.24
C
hild
ren
(<15
yea
rs)
75.15
To
tal
71.7
Ad
ults
(15+
yea
rs)
71.7
Fe
mal
e(1
5+ y
ears
)
88.7
C
hild
ren
(<15
yea
rs)
1.42
Ad
ults
(15+
yea
rs)
0.70
Fe
mal
e(1
5+ y
ears
)
0.14
C
hild
ren
(<15
yea
rs)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
80.3
6 To
tal
80.1
Adul
ts (1
5+ y
ears
)
86.0
Fem
ale
(15+
yea
rs)
84.8
Chi
ldre
n (<
15 y
ears
)
1.39
[1.0
0-2
.00
]
6.39
Tota
l[3
.86-
10.6
9]
[3.6
8-10
.18]
[1.10
-3.8
4][0
.13-0
.40
]
1.57
Tota
l [0
.70
-3.5
3]
[0.6
0-3
.28]
[0.2
9-1.6
2][0
.08-
0.23
]
[0.0
1-0.
05]
[0.0
1-0.
05]
0.0
2 To
tal
[0.0
1-0.
05]
0.47
To
tal
[0.3
7-0.
59]
[0.3
5-0.
58]
[0.3
8-0.
61]
269.
47 T
otal
[2
18.7
1-33
8.71
]
[213
.09-
329.
05]
[10
8.98
-167
.44]
[6.17
-10.
99]
Karn
atak
a
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
100.
0A
IDS
mor
talit
y pe
r 10
0,0
00
pop
ulat
ion
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.3
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.07.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
54
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
55
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
09
Fem
ale
0.0
7 M
ale
0.0
3 Fe
mal
e0.
02
23.4
6Ad
ults
(15+
yea
rs)
10.8
4 Fe
mal
e(1
5+ y
ears
)
0.75
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.49
Ad
ults
(15+
yea
rs)
0.19
Fe
mal
e(1
5+ y
ears
)
0.0
3 C
hild
ren
(<15
yea
rs)
24.2
0
Tota
l
19.2
Adul
ts(1
5+ y
ears
)
20.2
Fe
mal
e(1
5+ y
ears
)
67.3
C
hild
ren
(<15
yea
rs)
0.76
Adul
ts(1
5+ y
ears
)
0.35
Fe
mal
e(1
5+ y
ears
)
0.0
3 C
hild
ren
(<15
yea
rs)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
53.3
7 To
tal
53.6
Adul
ts (1
5+ y
ears
)
64.6
Fem
ale
(15+
yea
rs)
48.6
Chi
ldre
n (<
15 y
ears
)
0.16
[0
.12-0
.24]
0.53
Tota
l[0
.35-
0.99
]
[0.3
2-0.
93]
[0.11
-0.4
2][0
.02-
0.0
6]
0.80
Tota
l [0
.50
-1.5
9]
[0.4
7-1.
53]
[0.2
2-0.
70]
[0.0
2-0.
06]
[0.0
1-0.
04]
[0.0
1-0.
05]
0.0
2 To
tal
[0.0
1-0.
05]
0.0
8To
tal
[0.0
7-0.
11]
[0.0
7-0.
12]
24.2
1 Tot
al
[20.
18-3
1.83
]
[19.
62-3
0.90
][9
.04-
14.5
1][0
.61-
1.00
]
Kera
la
[0.0
6-0.
10]
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
01.0H
IV in
cide
nce
per 1
,00
0 u
ninf
ecte
d po
pula
tion
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
10.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.01.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
12
Fem
ale
0.0
7 M
ale
0.0
5
Fem
ale
0.0
3 56
.93
Adul
ts(1
5+ y
ears
)
20.3
0
Fem
ale
(15+
yea
rs)
2.35
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
1.69
Ad
ults
(15+
yea
rs)
0.38
Fe
mal
e(1
5+ y
ears
)
0.11
C
hild
ren
(<15
yea
rs)
16.2
4 To
tal
8.4
Ad
ults
(15+
yea
rs)
9.1
Fem
ale
(15+
yea
rs)
67.8
C
hild
ren
(<15
yea
rs)
2.74
Ad
ults
(15+
yea
rs)
0.90
Fe
mal
e(1
5+ y
ears
)
0.14
C
hild
ren
(<15
yea
rs)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
53.16
To
tal
52.2
Adul
ts (1
5+ y
ears
)
66.1
Fem
ale
(15+
yea
rs)
63.5
Chi
ldre
n (<
15 y
ears
)
0.61
[0.4
3-0.
86]
1.82
To
tal
[1.14
-2.9
6]
[1.0
5-2.
76]
[0.2
0-0
.71]
[0.0
7-0.
18]
2.89
Tota
l[1
.60
-4.7
7]
[1.5
0-4
.55]
[0.4
7-1.4
8][0
.09-
0.22
]
[0.0
1-0.
04]
[0.0
3-0.
08]
0.0
4To
tal
[0.0
2-0.
06]
0.10
Tota
l[0
.08-
0.14
]
[0.0
9-0.
17]
[0.0
6-0.
10]
59.3
0 T
otal
[4
6.34
-80.
10]
[44.
48-7
6.90
][1
6.14
-26.
60]
[1.8
4-3.
12]
Mad
hya
Prad
esh
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
00.1
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
10.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.01.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
56
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
57
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
38
Fem
ale
0.33
M
ale
0.0
7 Fe
mal
e0.
07
383.
79Ad
ults
(15+
yea
rs)
167.
78
Fem
ale
(15+
yea
rs)
12.5
5 C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
9.19
Ad
ults
(15+
yea
rs)
2.46
Fe
mal
e(1
5+ y
ears
)
0.49
C
hild
ren
(<15
yea
rs)
38.3
8 To
tal
35.3
Ad
ults
(15+
yea
rs)
31.0
Fe
mal
e(1
5+ y
ears
)
61.8
C
hild
ren
(<15
yea
rs)
7.92
Ad
ults
(15+
yea
rs)
3.75
Fe
mal
e(1
5+ y
ears
)
0.61
C
hild
ren
(<15
yea
rs)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
71.8
1 To
tal
72.0
Adul
ts (1
5+ y
ears
)
76.7
Fem
ale
(15+
yea
rs)
67.7
Chi
ldre
n (<
15 y
ears
)
3.0
1[2
.27-
4.12
]
9.69
Tota
l[4
.91-
21.0
5]
[4.6
9-20
.24]
[0.9
7-6.
10]
[0.2
0-0
.91]
8.54
Tota
l [3
.77-
20.10
]
[3.3
5-19
.05]
[1.5
9-9.
22]
[0.3
7-1.0
8]
[0.0
3-0.
17]
[0.0
3-0.
17]
0.0
7To
tal
[0.0
3-0.
16]
0.36
Tota
l[0
.25-
0.53
]
[0.2
6-0.
56]
[0.2
3-0.
49]
396.
35 T
otal
[2
88.6
0-5
77.0
1]
[278
.09-
560.
00
][1
19.6
4-24
2.42
][8
.94-
17.4
4]
Mah
aras
htra
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.3
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
50.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
7.0A
dult
(15–
49 y
ears
) HIV
pre
vale
nce
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e1.
22
Fem
ale
1.13
Mal
e0.
34
Fem
ale
0.33
27
.04
Adul
ts(1
5+ y
ears
)
12.8
5 Fe
mal
e(1
5+ y
ears
)
1.52
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.99
Ad
ults
(15+
yea
rs)
0.39
Fe
mal
e(1
5+ y
ears
)
0.0
8 C
hild
ren
(<15
yea
rs)
29.0
9 To
tal
19.5
Adul
ts(1
5+ y
ears
)
16.2
Fe
mal
e(1
5+ y
ears
)
73.0
C
hild
ren
(<15
yea
rs)
0.89
Adul
ts(1
5+ y
ears
)
0.43
Fe
mal
e(1
5+ y
ears
)
0.0
6 C
hild
ren
(<15
yea
rs)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
52.4
2 To
tal
52.3
Adul
ts (1
5+ y
ears
)
55.3
Fem
ale
(15+
yea
rs)
54.1
Chi
ldre
n (<
15 y
ears
)
0.36
[0
.26-
0.50
]
1.0
8To
tal
[0.7
2-1.
66]
[0.6
5-1.5
4][0
.23-
0.67
][0
.06-
0.12
]
0.96
To
tal
[0.4
8-1.
69]
[0.4
3-1.
59]
[0.2
1-0.
78]
[0.0
4-0.
09]
[0.16
-0.5
9][0
.17-0
.62]
0.34
To
tal
[0.17
-0.5
9]
1.18
Tota
l[0
.97-
1.46
]
[0.9
9-1.
52]
28.5
6 To
tal
[23.
55-3
5.19
]
[22.
20-3
3.43
][1
0.63
-15.
95]
[1.2
5-1.8
7]
Man
ipur
[0.9
3-1.4
0]
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
00.7
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
150.
0A
IDS
mor
talit
y pe
r 10
0,0
00
pop
ulat
ion
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
10.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
58
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
59
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
57
Fem
ale
0.51
M
ale
0.24
Fe
mal
e0.
22
10.6
9 Ad
ults
(15+
yea
rs)
5.0
4 Fe
mal
e(1
5+ y
ears
)
0.58
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.21
Ad
ults
(15+
yea
rs)
0.11
Fe
mal
e(1
5+ y
ears
)
0.0
5 C
hild
ren
(<15
yea
rs)
48.6
7 To
tal
48.9
Ad
ults
(15+
yea
rs)
44.7
Fe
mal
e(1
5+ y
ears
)
46.7
C
hild
ren
(<15
yea
rs)
0.68
Ad
ults
(15+
yea
rs)
0.33
Fe
mal
e(1
5+ y
ears
)
0.0
4 C
hild
ren
(<15
yea
rs)
Incr
ease
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
135.
53+
Tota
l
183.
2+Ad
ults
(15+
yea
rs)
162.
8+Fe
mal
e (1
5+ y
ears
)
22.2
+C
hild
ren
(<15
yea
rs)
0.28
[0
.23-
0.34
]
0.36
Tota
l[0
.26-
0.45
]
[0.3
0-0
.38]
[0.0
7-0.
15]
[0.0
4-0.
06]
0.73
Tota
l[0
.57-
0.98
]
[0.5
3-0.
91]
[0.2
5-0.
43]
[0.0
4-0.
06]
[0.17
-0.3
0]
[0.18
-0.3
1]
0.23
Tota
l [0
.18-0
.31]
0.54
To
tal
[0.4
6-0.
63]
[0.4
8-0.
67]
[0.4
3-0.
60]
11.2
8 To
tal
[9.5
1-13
.08]
[9.0
1-12
.51]
[4.2
6-5.
91]
[0.4
9-0.
65]
Meg
hala
ya
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
00.7
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
25.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
2.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e2.
58
Fem
ale
2.0
6 M
ale
1.34
Fem
ale
1.0
2 19
.33
Adul
ts(1
5+ y
ears
)
8.38
Fe
mal
e(1
5+ y
ears
)
0.71
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Incr
ease
/Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.28
Ad
ults
(15+
yea
rs)
0.11
Fe
mal
e(1
5+ y
ears
)
0.0
54
Chi
ldre
n(<
15 y
ears
)
0.51
- To
tal
3.0
+Ad
ults
(15+
yea
rs)
2.6+
Fe
mal
e(1
5+ y
ears
)
47.9
- C
hild
ren
(<15
yea
rs)
1.32
Ad
ults
(15+
yea
rs)
0.55
Fe
mal
e(1
5+ y
ears
)
0.0
5 C
hild
ren
(<15
yea
rs)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
50.0
To
tal
53.5
Adul
ts (1
5+ y
ears
)
49.6
Fem
ale
(15+
yea
rs)
16.9
Chi
ldre
n (<
15 y
ears
)
0.27
[0.2
1-0.
33]
0.34
Tota
l[0
.21-
0.52
]
[0.17
-0.4
5][0
.06-
0.19
][0
.03-
0.07
]
1.37
Tota
l [0
.85-
1.96
]
[0.8
1-1.8
9][0
.33-
0.79
][0
.03-
0.0
6]
[0.6
3-1.4
6][0
.83-
1.94]
1.18
Tota
l [0
.73-
1.70
]
2.32
Tota
l[1
.85-
2.84
]
[2.0
3-3.
18]
20.0
5 To
tal
[16.
12-2
4.62
]
[15.
48-2
3.76
][6
.80
-10.
21]
[0.5
8-0.
87]
Miz
oram
[1.6
5-2.
52]
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
2.0
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
100.
0A
IDS
mor
talit
y pe
r 10
0,0
00
pop
ulat
ion
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
10.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
60
61
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e1.
50
Fem
ale
1.41
M
ale
0.75
Fe
mal
e0.
71
21.6
5Ad
ults
(15+
yea
rs)
9.99
Fe
mal
e(1
5+ y
ears
)
0.89
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Incr
ease
/Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.50
Ad
ults
(15+
yea
rs)
0.16
Fe
mal
e(1
5+ y
ears
)
0.0
6 C
hild
ren
(<15
yea
rs)
6.47
- To
tal
0.3-
Ad
ults
(15+
yea
rs)
3.8+
Fe
mal
e(1
5+ y
ears
)
62.4
- C
hild
ren
(<15
yea
rs)
1.48
Ad
ults
(15+
yea
rs)
0.68
Fe
mal
e(1
5+ y
ears
)
0.0
6 C
hild
ren
(<15
yea
rs)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
34.7
2 To
tal
33.9
Adul
ts (1
5+ y
ears
)
38.7
Fem
ale
(15+
yea
rs)
40.4
Chi
ldre
n (<
15 y
ears
)
0.40
[0.3
1-0.
50]
0.57
Tota
l[0
.33-
0.84
]
[0.2
8-0.
75]
[0.0
8-0.
26]
[0.0
4-0.
08]
1.55
Tota
l [1
.04-
2.0
5]
[0.9
9-1.9
6][0
.47-
0.91
][0
.04-
0.0
8]
[0.4
9-0.
95]
[0.5
2-1.0
1]
0.73
Tota
l [0
.49-
0.97
]
1.45
Tota
l[1
.15-1
.78]
[1.16
-1.8
3]
22.5
5 To
tal
[18.
05-
27.4
1]
[17.
34-2
6.32
][7
.93-
11.9
8][0
.69-
1.11]
Nag
alan
d
[1.12
-1.7
0]
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
01.5H
IV in
cide
nce
per 1
,00
0 u
ninf
ecte
d po
pula
tion
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
100.
0A
IDS
mor
talit
y pe
r 10
0,0
00
pop
ulat
ion
1.0A
dult
(15–
49 y
ears
) HIV
pre
vale
nce
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
15
Fem
ale
0.13
M
ale
0.0
5
Fem
ale
0.0
5 46
.81
Adul
ts(1
5+ y
ears
)
21.5
0
Fem
ale
(15+
yea
rs)
2.33
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
1.60
Ad
ults
(15+
yea
rs)
0.67
Fe
mal
e(1
5+ y
ears
)
0.12
C
hild
ren
(<15
yea
rs)
38.3
3 To
tal
34.2
Ad
ults
(15+
yea
rs)
29.8
Fe
mal
e(1
5+ y
ears
)
68.5
C
hild
ren
(<15
yea
rs)
2.0
3
Adul
ts(1
5+ y
ears
)
1.0
1 Fe
mal
e(1
5+ y
ears
)
0.13
C
hild
ren
(<15
yea
rs)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
32.7
3 To
tal
30.6
Adul
ts (1
5+ y
ears
)
34.9
Fem
ale
(15+
yea
rs)
51.7
Chi
ldre
n (<
15 y
ears
)
0.49
[0
.40
-0.6
1]
1.74
Tota
l[1
.28-
2.43
]
[1.17
-2.2
5][0
.46-
0.98
][0
.09-
0.17
]
2.17
Tota
l[1
.62-
2.97
]
[1.5
1-2.
79]
[0.74
-1.4
0]
[0.10
-0.17
]
[0.0
4-0.
07]
[0.0
4-0.
07]
0.0
5 To
tal
[0.0
4-0.
07]
0.14
Tota
l[0
.12-0
.17]
[0.13
-0.18
][0
.11-0
.16]
49.15
Tot
al
[42.
81-5
9.22
]
[40.
61-5
6.45
][1
8.57
-25.
79]
[1.9
6-2.
93]
Odi
sha
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.2
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
15.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.01.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
62
63
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
36Fe
mal
e0.
33M
ale
0.17
Fem
ale
0.14
4.
63Ad
ults
(15+
yea
rs)
1.87
Fe
mal
e(1
5+ y
ears
)
0.14
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.25
Ad
ults
(15+
yea
rs)
0.0
8 Fe
mal
e(1
5+ y
ears
)
0.0
08
Chi
ldre
n(<
15 y
ears
)
39.0
6 To
tal
38.2
Ad
ults
(15+
yea
rs)
48.1
Fem
ale
(15+
yea
rs)
63.2
C
hild
ren
(<15
yea
rs)
0.25
Ad
ults
(15+
yea
rs)
0.0
9 Fe
mal
e(1
5+ y
ears
)
0.0
07
Chi
ldre
n(<
15 y
ears
)
Incr
ease
/Dec
line
in A
IDS-
rela
ted
mor
talit
ysi
nce
2010
(%)
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
364.
29+
Tota
l
425.
0+
Adul
ts (1
5+ y
ears
)
285.
7+Fe
mal
e (1
5+ y
ears
)
11.1-
Chi
ldre
n (<
15 y
ears
)
0.0
3[0
.02-
0.0
6]
0.26
To
tal
[0.11
-0.5
0]
[0.10
-0.4
8][0
.02-
0.17
][0
.00
3-0.
01]
0.26
Tota
l[0
.10-0
.61]
[0.0
9-0.
59]
[0.0
3-0.
23]
[0.0
03-0
.01]
[0.0
5-0.
35]
[0.0
7-0.
40]
0.16
To
tal
[0.0
6-0.
38]
0.35
Tota
l[0
.20
-0.5
8]
[0.2
0-0
.62]
[0.19
-0.5
4]
4.77
Tot
al
[2.8
3-7.
84]
[2.7
4-7.
62]
[1.13
-2.9
8][0
.07-
0.22
]
Pudu
cher
ry
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.5
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
25.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
3.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
31
Fem
ale
0.23
M
ale
0.0
9 Fe
mal
e0.
07
64
.03
Adul
ts(1
5+ y
ears
)
24.7
0
Fem
ale
(15+
yea
rs)
1.80
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
1.33
Ad
ults
(15+
yea
rs)
0.45
Fe
mal
e(1
5+ y
ears
)
0.0
8 C
hild
ren
(<15
yea
rs)
36.6
0
Tota
l
33.6
Ad
ults
(15+
yea
rs)
30.9
Fe
mal
e(1
5+ y
ears
)
75.6
C
hild
ren
(<15
yea
rs)
2.30
Ad
ults
(15+
yea
rs)
0.91
Fe
mal
e(1
5+ y
ears
)
0.0
6 C
hild
ren
(<15
yea
rs)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
67.4
4 To
tal
67.9
Adul
ts (1
5+ y
ears
)
65.3
Fem
ale
(15+
yea
rs)
58.5
Chi
ldre
n (<
15 y
ears
)
0.46
[0
.36-
0.63
]
1.42
To
tal
[0.9
7-2.
33]
[0.9
0-2
.20
][0
.28-
0.77
][0
.06-
0.12
]
2.37
Tota
l [1
.40
-4.10
]
[1.3
4-3.
99]
[0.5
4-1.
55]
[0.0
4-0.
10]
[0.0
4-0.
12]
[0.0
5-0.
15]
0.0
8To
tal
[0.0
5-0.
14]
0.27
Tota
l[0
.22-
0.35
]
[0.2
5-0.
41]
65.8
3 To
tal
[54.
18-8
4.51
]
[52.
54-8
2.36
][2
0.22
-31.4
7][1
.47-
2.29
]
Punj
ab
[0.19
-0.2
9]
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
25.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.3
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
2.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
64
65
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
14
Fem
ale
0.0
9
Mal
e0.
04
Fem
ale
0.0
3 60
.29
Adul
ts(1
5+ y
ears
)
22.6
0
Fem
ale
(15+
yea
rs)
2.67
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.66
Ad
ults
(15+
yea
rs)
0.11
Fe
mal
e(1
5+ y
ears
)
0.0
5 C
hild
ren
(<15
yea
rs)
41.5
9 To
tal
39.6
Ad
ults
(15+
yea
rs)
35.3
Fe
mal
e(1
5+ y
ears
)
65.9
C
hild
ren
(<15
yea
rs)
2.64
Ad
ults
(15+
yea
rs)
1.0
1 Fe
mal
e(1
5+ y
ears
)
0.12
C
hild
ren
(<15
yea
rs)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
20.4
9 To
tal
7.9
Adul
ts (1
5+ y
ears
)
45.5
Fem
ale
(15+
yea
rs)
71.8
Chi
ldre
n (<
15 y
ears
)
0.86
[0
.64-
1.0
6]
0.71
To
tal
[0.3
6-1.
20]
[0.3
3-1.1
0]
[0.0
4-0.
22]
[0.0
2-0.
09]
2.77
Tota
l [1
.58-
3.98
]
[1.4
9-3.
83]
[0.5
4-1.4
5][0
.07-
0.16
]
[0.0
2-0.
04]
[0.0
2-0.
06]
0.0
4To
tal
[0.0
2-0.
05]
0.11
Tota
l[0
.08-
0.14
]
[0.10
-0.16
]
62.9
8 To
tal
[47.
59-7
6.40
]
[45.
55-7
3.23
][1
6.54
-27.
81]
[2.0
4-3.
21]
Raja
stha
n
[0.0
6-0.
11]
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.2
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
5.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
0.5
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
08
Fe
mal
e0.
05
M
ale
0.0
4 Fe
mal
e0.
03
0.33
Adul
ts(1
5+ y
ears
)
0.12
Fe
mal
e(1
5+ y
ears
)
0.0
1 C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.0
04
Ad
ults
(15+
yea
rs)
0.0
01
Fem
ale
(15+
yea
rs)
0.0
01
Chi
ldre
n(<
15 y
ears
)
34.3
8 To
tal
33.3
Ad
ults
(15+
yea
rs)
27.3
Fe
mal
e(1
5+ y
ears
)
50.0
C
hild
ren
(<15
yea
rs)
0.0
07
Adul
ts(1
5+ y
ears
)
0.0
08
Fem
ale
(15+
yea
rs)
0.0
01
Chi
ldre
n(<
15 y
ears
)
Stab
ility
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
0.0
To
tal
0.0
Adul
ts (1
5+ y
ears
)
0.0
Fem
ale
(15+
yea
rs)
0.0
Chi
ldre
n (<
15 y
ears
)
0.0
04
[0
.00
2-0.
00
9]
0.0
04
Tota
l[0
.00
1-0.
016
]
[0.0
01-
0.0
14]
[0.0
0-0
.004
][0
.00
-0.0
02]
0.0
2To
tal
[0.0
1-0.
08]
[0.0
2-0.
07]
[0.0
03-0
.03]
[0.0
0-0.
003]
[0.0
1-0.
10]
[0.0
1-0.
14]
0.0
3To
tal
[0.0
1-0.
12]
0.0
7To
tal
[0.0
3-0.
15]
[0.0
4-0.
17]
[0.0
3-0.
12]
0.35
Tot
al
[0.19
-0.7
6]
[0.17
-0.7
3][0
.06-
0.27
][0
.00
8-0.
02]
Sikk
im
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.05.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
0.5
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.2
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
66
67
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
24
Fem
ale
0.21
M
ale
0.0
4Fe
mal
e0.
03
151.
55Ad
ults
(15+
yea
rs)
69.8
4 Fe
mal
e(1
5+ y
ears
)
3.0
5 C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
2.94
Ad
ults
(15+
yea
rs)
0.92
Fe
mal
e(1
5+ y
ears
)
0.0
6 C
hild
ren
(<15
yea
rs)
44.3
8 To
tal
40.2
Ad
ults
(15+
yea
rs)
40.2
Fe
mal
e(1
5+ y
ears
)
81.6
C
hild
ren
(<15
yea
rs)
2.53
Ad
ults
(15+
yea
rs)
1.14
Fem
ale
(15+
yea
rs)
0.0
8 C
hild
ren
(<15
yea
rs)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
72.6
2 To
tal
72.1
Adul
ts (1
5+ y
ears
)
78.1
Fem
ale
(15+
yea
rs)
85.8
Chi
ldre
n (<
15 y
ears
)
0.85
[0
.56-
1.20
]
3.0
1To
tal
[1.6
7-5.
33]
[1.6
4-5.
16]
[0.4
4-1.7
9][0
.01-
0.13
]
2.62
Tota
l[1
.08-
4.90
]
[1.0
2-4.
75]
[0.4
6-2.
14]
[0.0
4-0.
14]
[0.0
1-0.
06]
[0.0
2-0.
07]
0.0
4To
tal
[0.0
1-0.
07]
0.23
Tota
l[0
.16-0
.29]
[0.17
-0.3
2][0
.15-0
.27]
154.
61 T
otal
[1
14.3
7-19
7.84
]
[112
.37-
193.
13]
[52.
22-8
9.12
][1
.99-
4.14
]
Tam
il N
adu
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.2
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
25.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
5.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
53
Fem
ale
0.44
M
ale
0.0
8
Fem
ale
0.0
7
153.
57Ad
ults
(15+
yea
rs)
69.9
9 Fe
mal
e(1
5+ y
ears
)
3.94
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
3.90
Ad
ults
(15+
yea
rs)
1.35
Fe
mal
e(1
5+ y
ears
)
0.17
C
hild
ren
(<15
yea
rs)
52.0
6 To
tal
49.3
Ad
ults
(15+
yea
rs)
49.2
Fe
mal
e(1
5+ y
ears
)
73.7
C
hild
ren
(<15
yea
rs)
2.64
Ad
ults
(15+
yea
rs)
1.13
Fem
ale
(15+
yea
rs)
0.17
C
hild
ren
(<15
yea
rs)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
72.6
4 To
tal
72.4
Adul
ts (1
5+ y
ears
)
75.2
Fem
ale
(15+
yea
rs)
76.8
Chi
ldre
n (<
15 y
ears
)
1.0
3 [0
.68-
1.52
]
4.0
8To
tal
[2.2
8-6.
84]
[2.2
4-6.
59]
[0.6
6-2.
29]
[0.0
7-0.
30]
2.82
To
tal
[1.0
6-5.
95]
[0.9
7-5.
65]
[0.4
1-2.
46]
[0.0
8-0.
29]
[0.0
2-0.
14]
[0.0
3-0.
18]
0.0
8To
tal
[0.0
3-0.
16]
0.49
Tota
l[0
.35-
0.66
]
[0.3
7-0.
74]
157.
51 T
otal
[1
14.9
5-21
3.21
]
[112
.01-
208.
27]
[51.9
7-92
.55]
[2.7
0-5
.50
]
Tela
ngan
a
[0.3
2-0.
59]
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
100.
0A
IDS
mor
talit
y pe
r 10
0,0
00
pop
ulat
ion
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.3
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
5.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
68
69
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
11
Fem
ale
0.0
8
Mal
e0.
13Fe
mal
e0.
10
2.79
Adul
ts(1
5+ y
ears
)
1.13
Fem
ale
(15+
yea
rs)
0.0
6 C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Incr
ease
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.0
1 Ad
ults
(15+
yea
rs)
0.0
05
Fem
ale
(15+
yea
rs)
0.0
04
Chi
ldre
n(<
15 y
ears
)
264.
52+
Tota
l
274.
6+
Adul
ts(1
5+ y
ears
)
275.
0+
Fem
ale
(15+
yea
rs)
100.
0+
Chi
ldre
n(<
15 y
ears
)
0.44
Ad
ults
(15+
yea
rs)
0.18
Fe
mal
e(1
5+ y
ears
)
0.0
1 C
hild
ren
(<15
yea
rs)
Incr
ease
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
80.0
+ To
tal
100.
0+
Adul
ts (1
5+ y
ears
)
66.7
+Fe
mal
e (1
5+ y
ears
)
33.3
+C
hild
ren
(<15
yea
rs)
0.0
3[0
.02-
0.0
4]
0.0
2 To
tal
[0.0
1-0.
04]
[0.0
06-
0.0
3][0
.00
2-0.
01]
[0.0
02-
0.0
06]
0.45
Tota
l[0
.29-
0.65
]
[0.2
7-0.
64]
[0.11
-0.2
6][0
.006
-0.0
1]
[0.0
6-0.
14]
[0.0
9-0.
19]
0.11
Tota
l [0
.07-
0.17
]
0.10
Tota
l[0
.07-
0.13
]
[0.0
8-0.
15]
[0.0
6-0.
11]
2.86
Tot
al
[2.0
4-3.
77]
[1.9
8-3.
68]
[0.8
0-1
.51]
[0.0
5-0.
08]
Trip
ura
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.2
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
5.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
0.5
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
16
Fem
ale
0.10
Mal
e0.
05
Fem
ale
0.0
4
10.5
4Ad
ults
(15+
yea
rs)
4.21
Fe
mal
e(1
5+ y
ears
)
0.40
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
0.32
Ad
ults
(15+
yea
rs)
0.0
9 Fe
mal
e(1
5+ y
ears
)
0.0
2 C
hild
ren
(<15
yea
rs)
46.0
9 To
tal
44.8
Ad
ults
(15+
yea
rs)
41.2
Fe
mal
e(1
5+ y
ears
)
65.5
C
hild
ren
(<15
yea
rs)
0.46
Ad
ults
(15+
yea
rs)
0.18
Fe
mal
e(1
5+ y
ears
)
0.0
2 C
hild
ren
(<15
yea
rs)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
14.2
1 To
tal
11.2
Adul
ts (1
5+ y
ears
)
15.6
Fem
ale
(15+
yea
rs)
44.4
Chi
ldre
n (<
15 y
ears
)
0.10
[0
.07-
0.13
]
0.34
Tota
l[0
.21-
0.54
]
[0.19
-0.5
0]
[0.0
4-0.
15]
[0.0
1-0.
03]
0.49
To
tal
[0.3
1-0.
77]
[0.2
9-0.
73]
[0.11
-0.2
9][0
.01-
0.0
29]
[0.0
2-0.
06]
[0.0
3-0.
08]
0.0
4To
tal
[0.0
3-0.
07]
0.13
Tota
l[0
.10-0
.17]
[0.12
-0.2
0]
10.9
6 T
otal
[8
.49-
14.19
]
[8.13
-13.
69]
[3.3
3-5.
44]
[0.3
2-0.
52]
Utt
arak
hand
[0.0
8-0.
13]
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
10.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.2
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
0.5
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
70
71
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
12
Fem
ale
0.0
7 M
ale
0.0
4Fe
mal
e0.
02
15
3.25
Adul
ts(1
5+ y
ears
)
55.0
8 Fe
mal
e(1
5+ y
ears
)
7.34
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
3.50
Ad
ults
(15+
yea
rs)
0.66
Fe
mal
e(1
5+ y
ears
)
0.37
C
hild
ren
(<15
yea
rs)
46.3
7 To
tal
45.0
Ad
ults
(15+
yea
rs)
45.3
Fe
mal
e(1
5+ y
ears
)
60.4
C
hild
ren
(<15
yea
rs)
6.28
Ad
ults
(15+
yea
rs)
2.0
6
Fem
ale
(15+
yea
rs)
0.44
C
hild
ren
(<15
yea
rs)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
37.7
To
tal
36.2
Adul
ts (1
5+ y
ears
)
58.0
Fem
ale
(15+
yea
rs)
48.9
Chi
ldre
n (<
15 y
ears
)
2.21
[1.7
2-2.
94]
3.87
Tota
l[1
.91-
6.89
]
[1.7
1-6.
29]
[0.2
6-1.4
6][0
.20
-0.5
8]
6.72
Tota
l[3
.93-
10.6
0]
[3.6
1-9.
97]
[1.19
-3.2
5][0
.29-
0.62
]
[0.0
1-0.
03]
[0.0
2-0.
06]
0.0
3 To
tal
[0.0
2-0.
05]
0.10
Tota
l[0
.07-
0.13
]
[0.0
9-0.
16]
[0.0
6-0.
10]
160.
60 T
otal
[1
20.7
8-21
3.63
]
[114
.97-
203.
68]
[40.
88-7
1.50
][5
.39-
9.97
]
Utt
ar P
rade
sh
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.0
10.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
0
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0.2
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.0
0.5
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
Adu
lt (1
5–49
yrs
) HIV
pr
eval
ence
(%)
Num
ber o
f peo
ple
livin
g w
ith
HIV
(in
thou
sand
)H
IV in
cide
nce
per 1
,00
0
unin
fect
ed p
opul
atio
n
Mal
e0.
10
Fem
ale
0.0
9M
ale
0.0
4 Fe
mal
e0.
04
71
.59
Adul
ts(1
5+ y
ears
)
31.5
4 Fe
mal
e(1
5+ y
ears
)
2.61
C
hild
ren
(<15
yea
rs)
New
HIV
infe
ctio
ns (i
n th
ousa
nd)
Incr
ease
/Dec
line
in n
ew H
IV
infe
ctio
ns s
ince
20
10 (%
)A
IDS-
rela
ted
mor
talit
y (in
thou
sand
)
1.30
Ad
ults
(15+
yea
rs)
0.50
Fe
mal
e(1
5+ y
ears
)
0.0
6 C
hild
ren
(<15
yea
rs)
0.51
+ To
tal
7.0
+ Ad
ults
(15+
yea
rs)
7.4+
Fe
mal
e(1
5+ y
ears
)
56.4
- C
hild
ren
(<15
yea
rs)
3.79
Ad
ults
(15+
yea
rs)
1.77
Fem
ale
(15+
yea
rs)
0.17
5 C
hild
ren
(<15
yea
rs)
Dec
line
in A
IDS-
rela
ted
mor
talit
y si
nce
2010
(%)
Nee
d fo
r ser
vice
s to
pre
vent
mot
her-
to-
child
tran
smis
sion
of H
IV (i
n th
ousa
nd)
70.3
4 To
tal
69.6
Adul
ts (1
5+ y
ears
)
71.2
Fem
ale
(15+
yea
rs)
80.1
Chi
ldre
n (<
15 y
ears
)
0.68
[0.4
5-1.
05]
1.37
To
tal
[0.6
8-2.
92]
[0.6
5-2.
77]
[0.2
1-1.1
0]
[0.0
2-0.
15]
3.97
Tota
l [1
.94-
6.98
]
[1.8
4-6.
69]
[0.8
6-3.
18]
[0.0
9-0.
28]
[0.0
2-0.
07]
[0.0
2-0.
08]
0.0
4 To
tal
[0.0
2-0.
07]
0.0
9 To
tal
[0.0
7-0.
13]
[0.0
7-0.
14]
74.2
0 T
otal
[5
2.65
-10
3.61
]
[50.
81-9
9.99
][2
2.53
-44.
40]
[1.8
3-3.
80]
Wes
t Ben
gal
[0.0
6-0.
12]
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
0
0.2
HIV
inci
denc
e pe
r 1,0
00
uni
nfec
ted
popu
latio
n
1990199119921993199419951996199719981999
20002001200220032004200520062007200820092010201120122013201420152016
20182019
2017
0.01.0
Adu
lt (1
5–49
yea
rs) H
IV p
reva
lenc
e
0.0
10.0
AID
S m
orta
lity
per 1
00,
00
0 p
opul
atio
n
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
72
Model-based biennial HIV estimations is undertaken under National AIDS Control Programme to provide update on the current status of the HIV epidemic on key epidemiological parameters of prevalence, incidence, AIDS-related mortality and EMTCT need. HIV Estimations 2019 is the latest round in the series of HIV Estimations process. This report presents the method and State/UT-wise findings on key epidemiological parameters from HIV Estimations 2019.